Entegris Declares Quarterly Cash Dividend

Entegris Declares Quarterly Cash Dividend

BILLERICA, Mass.–(BUSINESS WIRE)–
Entegris, Inc. (Nasdaq: ENTG), a leading supplier of advanced materials and process solutions for the semiconductor and other high-technology industries, today announced that its board of directors has authorized a quarterly cash dividend of $0.10 per share to be paid on May 21, 2025, to shareholders of record on the close of business on April 30, 2025.

ABOUT ENTEGRIS

Entegris is a leading supplier of advanced materials and process solutions for the semiconductor and other high-tech industries. Entegris has approximately 8,000 employees throughout its global operations and is ISO 9001 certified. It has manufacturing, customer service and/or research facilities in the United States, Canada, China, Germany, Israel, Japan, Malaysia, Singapore, South Korea, and Taiwan. Additional information can be found at www.entegris.com.

Investor Contact:

Bill Seymour

+ 1 952 556 1844

[email protected]

Media Contact:

Jessica Emond

Senior Director, Global Corporate Communications

+1 978 436 6520

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Technology Research Packaging Semiconductor Engineering Chemicals/Plastics Automotive Manufacturing Manufacturing Science

MEDIA:

Logo
Logo

United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.

United Therapeutics will host a public webcast Wednesday, April 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics’ website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location.

United Therapeutics: Enabling Inspiration

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

You can learn more about what it means to be a PBC here: unither.com/PBC.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of April 16, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

For Further Information Contact:

Dewey Steadman at (202) 919-4097 (media/investors)

Harry Silvers at (301) 578-1401 (investors)

https://ir.unither.com/contact-ir

KEYWORDS: United States North America North Carolina Maryland

INDUSTRY KEYWORDS: Health Surgery General Health Pharmaceutical Cardiology Biotechnology

MEDIA:

Glaukos Announces the Release of its 2024 Sustainability Report

Glaukos Announces the Release of its 2024 Sustainability Report

ALISO VIEJO, Calif.–(BUSINESS WIRE)–
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2024 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Report can be found on the company’s website here.

“I am proud to issue our sixth annual Sustainability Report, which highlights the significant progress we’ve made in advancing our core corporate sustainability goals that are aligned with our mission and key strategic plans,” said Thomas Burns, Glaukos chairman and chief executive officer. “We believe that our ongoing commitment to enhancing and expanding sustainability initiatives not only strengthens our organization but also positively impacts the communities we serve, while also helping to drive long-term value for our shareholders. The programs, policies and achievements detailed in this report provide compelling examples of our dedication to sustainability, an important pillar of both our culture and brand.”

Throughout 2024, Glaukos took significant steps to enhance its corporate sustainability efforts, achieving several key milestones, including:

  • Donated approximately $7 million in products to underserved regions globally, bringing our total product donations to over $17 million to date.
  • Contributed to community betterment through 45 philanthropic volunteer events in collaboration with 25 nonprofit organizations worldwide, totaling over 700 volunteer hours from our employees.
  • Expanded our patient services program to nearly 5,000 keratoconus patients, supporting them through every step of their journey from diagnosis to treatment. This brings the total number of keratoconus patients served to approximately 8,000 since the program’s launch in 2023.
  • Introduced a range of new employee benefits, including mental health support, flexible time off, a student loan repayment program, and international pension and supplemental health insurance.
  • Laid the groundwork for a new Patient Ambassador Program, in partnership with glaucoma advocacy groups, aimed at enhancing patient education and empowerment.
  • Collaborated with various patient advocacy organizations to raise awareness and provide educational resources for interventional glaucoma.
  • Implemented a two-site product distribution model in the U.S., which began in 2023, leading to reduced shipping costs, the elimination of approximately 20 million air miles, and a reduction of roughly 4,000 tons of greenhouse gas emissions.
  • Announced plans to construct a new research, development and manufacturing facility in Huntsville, Alabama, to bolster our infrastructure and support future growth.
  • Advanced our iDose Your Dose philanthropic initiative, which ensures that for every iDose® TR unit sold, an equal number will be donated to qualifying charitable requests in the U.S. and globally, subject to independent eligibility requirements.

For additional information and highlights, please see Glaukos’ 2024 Sustainability Report, which can be found on the company’s website here.

Glaukos’ sustainability initiatives are overseen by the company’s board of directors.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, our ability to achieve the sustainability goals and targets identified in the sustainability report. Historical, current and forward-looking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. The information included in, and any issues identified as material for purposes of this document may not be considered material for Securities and Exchange Commission (SEC) reporting purposes. In the context of this disclosure, the term “material” is distinct from, and should not be confused with, such term as defined for SEC reporting purposes. These and other risks, uncertainties and factors related to Glaukos, and our business are described in detail under the caption “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 25, 2025. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Media Contact:

Andria Arena

[email protected]

Investor Contact:

Chris Lewis

Vice President, Investor Relations & Corporate Affairs

(949) 481-0510

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: FDA Health Human Resources Pharmaceutical Surgery Professional Services Optical Environmental, Social and Governance (ESG) Other Philanthropy Philanthropy Environment Medical Devices Sustainability Health Technology

MEDIA:

Logo
Logo

K2 Cyber Partners with TransUnion to Deliver Cybersecurity Protection and Services

K2 Cyber Partners with TransUnion to Deliver Cybersecurity Protection and Services

CHAPEL HILL, N.C.–(BUSINESS WIRE)–K2 Cyber, a K2 Insurance Services brand and the provider of Intelligent Cyber Insurance™, announces today its partnership with TransUnion for Commercial Cyber Services and Cyber Claims Management. Through this collaboration, K2 Cyber policyholders will gain access to TransUnion’s TruEmpower™ CyberScout solution, a comprehensive service designed to help companies address and mitigate risks associated with cyber incidents.

This partnership enhances K2 Cyber’s offerings by providing cyber claims management, incident response remediation and forensics consultation, advanced cyber and business ID theft prevention tools, and a crisis hotline for proactive questions. Policyholders will also benefit from ongoing care, education, and triage services, ensuring they are well-equipped to handle and recover from any cyber threats that may arise.

“At K2 Cyber, we are committed to delivering unparalleled protection and support to our policyholders,” said Keith Moore, CEO and founder of K2 Cyber. “Partnering with TransUnion allows us to enhance our offerings with cutting-edge solutions that not only address current cyber threats but also empower our clients to proactively safeguard their digital environments, helping us redefine cyber risk management for the SMB sector.”

“The aftermath of a data breach can feel chaotic for a business owner, and it’s difficult to even know how to begin addressing the situation,” said Matt Cullina, Head of TransUnion’s Global Cyber Insurance Business. “CyberScout’s services are both technical and consultative to assess and repair the damage, while helping small business owners navigate the process—so they can focus on protecting their customers as well as their brand.”

About K2 Cyber:

K2 Cyber is the cutting-edge provider of Intelligent Cyber Insurance™, dedicated to cultivating winners in today’s complex SMB digital landscape through continuous risk engineering, innovative prevention and mitigation tools, and comprehensive cyber education. By empowering insureds with resources typically beyond their reach, our influence drives positive change on a broader scale. Backed by a team with deep cyber insurance, technology and cybersecurity expertise, K2 Cyber is redefining cyber risk management for the SMB sector. For more information, visit k2cyber.ai.

K2 Cyber is a K2 Insurance Services brand.

About K2 Insurance Services:

K2 Insurance Services is an insurance services holding company that owns and controls a diverse set of MGAs, marketing, underwriting and servicing nearly $2 billion annually in niche commercial and personal insurance premiums. Our mission is to protect what matters most to our partners and clients through personalized and specialty insurance products by distributing innovative programs and products through trusted direct, retail and wholesale channels. Formed and led by successful insurance industry veterans and backed by Warburg Pincus, K2 is leading the way with specialty insurance programs

About TransUnion (NYSE: TRU):

TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world. http://www.transunion.com/business

Media Contact:

Katherine Moura, Chief Brand & Communications Officer

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Technology Professional Services Insurance Security

MEDIA:

Logo
Logo

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

PR Newswire

— SIGNAL-AA Part B topline data readout on-track for 1H’26 —


WALTHAM, Mass.
, April 16, 2025 /PRNewswire/ — Q32 Bio Inc. (Nasdaq: QTTB) (“Q32 Bio” or the “Company”), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the Company has dosed the first patients in both the Part A open-label extension (OLE) and Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with alopecia areata (AA).

“Dosing the first patients in both the Part A OLE and Part B of our SIGNAL-AA trial highlights our ongoing momentum in the clinical development of bempikibart as a potential treatment for AA,” said Jodie Morrison, Chief Executive Officer of Q32 Bio. “Based upon the encouraging clinical activity observed to date, including patients with continued responses in long-term follow-up months after completing treatment, robust pharmacologic data and a well-tolerated safety profile, we believe bempikibart has the potential to transform the AA treatment paradigm as a new and differentiated therapy for patients, if approved.”

Q32 previously announced results from Part A of the SIGNAL-AA Phase 2a clinical trial, a randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating bempikibart in adult patients with severe and very severe AA (baseline Severity of Alopecia Tool (SALT) scores of 50-100) treated over 24 weeks, with follow-up through 36 weeks. Results reported to date have demonstrated encouraging clinical activity, including improvement from baseline on SALT score and meaningful achievement of SALT-20 (SALT score less than or equal to 20) response through week 36. Part A of the SIGNAL-AA clinical trial has been completed. Through additional post-clinical trial data collection after 36 weeks, continued responses were observed in multiple patients through week 55, approximately seven months post last dose, along with continued SALT reductions in some patients, despite dosing through only 24 weeks. The Company believes these findings may be suggestive of a remittive effect, durability of response, and a key differentiation from currently approved therapies. Based on re-consent rates and strong patient demand for continued dosing, Q32 Bio initiated the OLE for eligible patients that completed Part A to enable longer-term follow-up of patients.

Part B of the SIGNAL-AA Phase 2a clinical trial is an open-label clinical trial, dosing approximately 20 evaluable severe or very severe AA patients with bempikibart for 36 weeks, with follow-up out to 52 weeks. Dosing will include an initial loading regimen of 200mg of bempikibart dosed weekly over four weeks, followed by a maintenance dose of 200mg every-other-week over a 32-week period for a total dosing period of 36 weeks. Efficacy will be evaluated on the basis of mean percentage change from baseline in SALT scores as well as the proportion of subjects achieving various relative and absolute SALT improvements at week 36, with follow-up through week 52. The trial is intended to support advancement into pivotal trials upon completion, pending review of the results. Q32 Bio expects to report topline data from SIGNAL-AA Part B in the first half of 2026. 

About Q32 Bio

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

For more information, visit www.Q32Bio.com.

  1. National Alopecia Areata Foundation

Availability of Other Information About Q32 Bio

Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com, including, but not limited to, the Company’s disclosures, investor presentations and FAQs, Securities and Exchange Commission (the “SEC”) filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of the Company’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, Q32 Bio’s beliefs, observations, expectations and assumptions regarding the data reported to date from Part A of the SIGNAL-AA Phase 2a clinical trial, the plan, purpose and timing of Part B of the SIGNAL-AA Phase 2a clinical trial and the anticipated timing of its data, and the safety, tolerability, clinical activity, potential efficacy and potential benefits of bempikibart; which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

Forward-looking statements are based on management’s current beliefs and assumptions, which are subject to risks and uncertainties and are not guarantees of future performance. Such risks and uncertainties include, among others, the risk that additional data, or the results of ongoing data analyses, may not support the Company’s current beliefs and expectations for bempikibart, including with respect to the durability of clinical responses, the risk that ongoing and future clinical studies, including Part B of the SIGNAL-AA Phase 2a clinical trial, may not be completed by the first half of 2026 or at all, might be more costly than expected or might not yield anticipated results, and such other risks and uncertainties identified in the Company’s periodic, current and other filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequent filings with the SEC, which are available at the SEC’s website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect the Company’s results of operations and its cash flows, which would, in turn, have a significant and adverse impact on the Company’s stock price. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Contacts:
Investors: Brendan Burns
Argot Partners
212.600.1902
[email protected]

Media: David Rosen
Argot Partners
646.461.6387
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-doses-first-patients-in-both-part-a-open-label-extension-and-part-b-of-signal-aa-phase-2a-trial-evaluating-bempikibart-in-alopecia-areata-302429636.html

SOURCE Q32 Bio

Travelers Reports First Quarter Net Income of $395 Million and Core Income of $443 Million

Travelers Reports First Quarter Net Income of $395 Million and Core Income of $443 Million

First Quarter 2025 Net Income per Diluted Share of $1.70 and Core Income per Diluted Share of $1.91

Board of Directors Declares 5% Increase in Regular Quarterly Cash Dividend to $1.10 per Share

  • Exceptional underlying underwriting income of $1.583 billion pre-tax, up 32%.
  • Consolidated combined ratio of 102.5%; and underlying combined ratio of 84.8%, a 2.9 point improvement.
  • Catastrophe losses of $2.266 billion pre-tax, primarily driven by the January 2025 California wildfires.
  • Net favorable prior year reserve development of $378 million pre-tax.
  • Net investment income increased 10% pre-tax over the prior year quarter.
  • Operating cash flows of $1.360 billion.

NEW YORK–(BUSINESS WIRE)–
The Travelers Companies, Inc. today reported net income of $395 million, or $1.70 per diluted share, for the quarter ended March 31, 2025, compared to $1.123 billion, or $4.80 per diluted share, in the prior year quarter. Core income in the current quarter was $443 million, or $1.91 per diluted share, compared to $1.096 billion, or $4.69 per diluted share, in the prior year quarter. Core income decreased primarily due to higher catastrophe losses, partially offset by a higher underlying underwriting gain (i.e., excluding net prior year reserve development and catastrophe losses), higher net favorable prior year reserve development and higher net investment income. Net realized investment losses in the current quarter were $61 million pre-tax ($48 million after-tax), compared to net realized investment gains of $35 million pre-tax ($27 million after-tax) in the prior year quarter. Per diluted share amounts benefited from the impact of share repurchases.

Consolidated Highlights

($ in millions, except for per share amounts, and after-tax, except for premiums and revenues)

 

Three Months Ended March 31,

 

 

2025

 

2024

 

Change

 

Net written premiums

 

$

10,515

 

 

$

10,182

 

 

3

%

 

 

 

 

 

 

 

 

 

Total revenues

 

$

11,810

 

 

$

11,228

 

 

5

 

 

Net income

 

$

395

 

 

$

1,123

 

 

(65

)

 

per diluted share

 

$

1.70

 

 

$

4.80

 

 

(65

)

 

Core income

 

$

443

 

 

$

1,096

 

 

(60

)

 

per diluted share

 

$

1.91

 

 

$

4.69

 

 

(59

)

 

Diluted weighted average shares outstanding

 

 

230.4

 

 

 

232.0

 

 

(1

)

 

Combined ratio

 

 

102.5

%

 

 

93.9

%

 

8.6

 

pts

Underlying combined ratio

 

 

84.8

%

 

 

87.7

%

 

(2.9

)

pts

Return on equity

 

 

5.6

%

 

 

18.0

%

 

(12.4

)

pts

Core return on equity

 

 

5.6

%

 

 

15.4

%

 

(9.8

)

pts

 

 

As of

 

Change From

 

 

March 31, 2025

 

December 31,

2024

 

March 31, 2024

 

December 31,

2024

 

March 31, 2024

Book value per share

 

$

124.43

 

$

122.97

 

$

109.28

 

1

%

 

14

%

Adjusted book value per share

 

 

138.99

 

 

139.04

 

 

125.53

 

%

 

11

%

See Glossary of Financial Measures for definitions and the statistical supplement for additional financial data.

“We are pleased to report a substantial profit for the quarter despite the devastating January California wildfires,” said Alan Schnitzer, Chairman and Chief Executive Officer. “We earned core income of $443 million, or $1.91 per diluted share, as outstanding underlying results, strong net favorable prior year reserve development and higher investment income more than offset catastrophe losses. Underlying underwriting income of $1.6 billion pre-tax was up more than 30% over the prior year quarter, driven by strong net earned premiums of $10.7 billion and a consolidated underlying combined ratio that improved 2.9 points to an excellent 84.8%. All three segments contributed to these terrific underlying results with strong and higher net earned premiums and excellent underlying profitability. All three segments also contributed meaningful levels of net favorable prior year reserve development. In addition, our high-quality investment portfolio continued to perform well, generating after-tax net investment income of $763 million, driven by strong and reliable returns from our growing fixed income portfolio and positive returns from our thoughtfully managed alternative portfolio.

“During the quarter, we returned nearly $600 million of excess capital to shareholders, including $358 million of share repurchases. In recognition of our strong financial position and confidence in the outlook for our business, I am pleased to share that our Board of Directors declared a 5% increase in our quarterly cash dividend to $1.10 per share, marking 21 consecutive years of dividend increases with a compound annual growth rate of 8% over that period.

“Through continued terrific marketplace execution across all three segments, we grew our net written premiums in the first quarter to $10.5 billion. In Business Insurance, we grew net written premiums by 2% to a record $5.7 billion, after the ceded premium impact of the enhanced casualty reinsurance program that we announced last quarter. As we previewed, this reinsurance change reduced the segment’s net written premium growth in the quarter by 4 points, as the full year’s worth of ceded premium was booked in the first quarter. Renewal premium change in the segment remained very strong at 9.2%, while retention improved nearly two points sequentially to 86%. New business for the segment was a record $735 million. In Bond & Specialty Insurance, we grew net written premiums by 6% to $1.0 billion, with excellent retention of 89% in our high-quality management liability business. In our industry-leading surety business, we grew net written premiums by 13%. In Personal Insurance, net written premiums grew 5% to $3.8 billion, driven by strong renewal premium change, particularly in our Homeowners business.

“Our trailing twelve-month core return on equity of 14.5% reflects the strong momentum we have at our backs as we benefit from investments we have made over a number of years. We are confident that the strategic initiatives we have underway and on our roadmap will continue to extend and deepen our competitive advantages, drive profitable growth and contribute to leading shareholder value over time.”

Consolidated Results

 

 

Three Months Ended March 31,

 

($ in millions and pre-tax, unless noted otherwise)

 

2025

 

2024

 

Change

 

Underwriting gain (loss):

 

$

(305

)

 

$

577

 

 

$

(882

)

 

Underwriting gain (loss) includes:

 

 

 

 

 

 

 

Net favorable prior year reserve development

 

 

378

 

 

 

91

 

 

 

287

 

 

Catastrophes, net of reinsurance

 

 

(2,266

)

 

 

(712

)

 

 

(1,554

)

 

Net investment income

 

 

930

 

 

 

846

 

 

 

84

 

 

Other income (expense), including interest expense

 

 

(96

)

 

 

(88

)

 

 

(8

)

 

Core income before income taxes

 

 

529

 

 

 

1,335

 

 

 

(806

)

 

Income tax expense

 

 

86

 

 

 

239

 

 

 

(153

)

 

Core income

 

 

443

 

 

 

1,096

 

 

 

(653

)

 

Net realized investment gains (losses) after income taxes

 

 

(48

)

 

 

27

 

 

 

(75

)

 

Net income

 

$

395

 

 

$

1,123

 

 

$

(728

)

 

 

 

 

 

 

 

 

 

Combined ratio

 

 

102.5

%

 

 

93.9

%

 

 

8.6

 

pts

Impact on combined ratio

 

 

 

 

 

 

 

Net favorable prior year reserve development

 

 

(3.5

)

pts

 

(0.9

)

pts

 

(2.6

)

pts

Catastrophes, net of reinsurance

 

 

21.2

 

pts

 

7.1

 

pts

 

14.1

 

pts

Underlying combined ratio

 

 

84.8

%

 

 

87.7

%

 

 

(2.9

)

pts

 

 

 

 

 

 

 

 

Net written premiums

 

 

 

 

 

 

 

Business Insurance

 

$

5,698

 

 

$

5,596

 

 

 

2

%

 

Bond & Specialty Insurance

 

 

999

 

 

 

943

 

 

 

6

 

 

Personal Insurance

 

 

3,818

 

 

 

3,643

 

 

 

5

 

 

Total

 

$

10,515

 

 

$

10,182

 

 

 

3

%

 

First Quarter 2025 Results

(All comparisons vs. first quarter 2024, unless noted otherwise)

Net income of $395 million decreased $728 million, driven by lower core income and net realized investment losses compared to net realized investment gains in the prior year quarter. Core income of $443 million decreased $653 million, primarily due to higher catastrophe losses, partially offset by a higher underlying underwriting gain, higher net favorable prior year reserve development and higher net investment income. The underlying underwriting gain benefited from higher business volumes. Net realized investment losses were $61 million pre-tax ($48 million after-tax), compared to net realized investment gains of $35 million pre-tax ($27 million after-tax) in the prior year quarter.

Combined ratio:

  • The combined ratio of 102.5% increased 8.6 points due to higher catastrophe losses (14.1 points), partially offset by an improvement in the underlying combined ratio (2.9 points) and higher net favorable prior year reserve development (2.6 points).
  • The underlying combined ratio improved 2.9 points to an excellent 84.8%. See below for further details by segment.
  • Net favorable prior year reserve development occurred in all segments. See below for further details by segment.
  • Catastrophe losses primarily resulted from the January 2025 California wildfires, which were $1.731 billion pre-tax ($1.368 billion after-tax), as well as severe wind and hail storms in multiple states.

Net investment income of $930 million pre-tax ($763 million after-tax) increased 10%. Income from the long-term fixed income investment portfolio increased over the prior year quarter due to a higher long-term average yield and growth in average invested assets. Income from the short-term fixed income investment portfolio decreased from the prior year quarter due to a lower short-term average yield. Income from the non-fixed income investment portfolio decreased from the prior year quarter primarily due to lower private equity partnership returns, partially offset by higher real estate partnership returns.

Net written premiums of $10.515 billion increased 3%. Net written premium growth was adversely impacted by higher levels of ceded premium primarily associated with an enhanced casualty reinsurance program in Business Insurance. See below for further details by segment.

Shareholders’ Equity

Shareholders’ equity of $28.191 billion increased 1% over year-end 2024, primarily due to net income of $395 million and lower net unrealized investment losses, partially offset by common share repurchases and dividends to shareholders. Net unrealized investment losses included in shareholders’ equity were $4.172 billion pre-tax ($3.299 billion after-tax), compared to $4.609 billion pre-tax ($3.640 billion after-tax) at year-end 2024. The decrease in net unrealized investment losses was driven primarily by lower interest rates. Book value per share of $124.43 increased 14% over March 31, 2024 and 1% over year-end 2024. Adjusted book value per share of $138.99, which excludes net unrealized investment gains (losses), increased 11% over March 31, 2024 and was comparable with year-end 2024.

The Company repurchased 1.4 million shares during the first quarter at an average price of $252.68 per share for a total cost of $358 million. At March 31, 2025, the Company had $4.790 billion of capacity remaining under its share repurchase authorizations approved by the Board of Directors. At the end of the quarter, statutory capital and surplus was $27.785 billion, and the ratio of debt-to-capital was 22.2%. The ratio of debt-to-capital excluding after-tax net unrealized investment gains (losses) included in shareholders’ equity was 20.3%, within the Company’s target range of 15% to 25%.

The Board of Directors declared a 5% increase in the regular quarterly dividend to $1.10 per share. The dividend is payable June 30, 2025, to shareholders of record at the close of business on June 10, 2025.

Business Insurance Segment Financial Results

 

 

Three Months Ended March 31,

 

($ in millions and pre-tax, unless noted otherwise)

 

2025

 

2024

 

Change

 

Underwriting gain:

 

$

195

 

 

$

334

 

 

$

(139

)

 

Underwriting gain includes:

 

 

 

 

 

 

 

Net favorable prior year reserve development

 

 

74

 

 

 

 

 

 

74

 

 

Catastrophes, net of reinsurance

 

 

(509

)

 

 

(209

)

 

 

(300

)

 

Net investment income

 

 

656

 

 

 

609

 

 

 

47

 

 

Other income (expense)

 

 

(9

)

 

 

(9

)

 

 

 

 

Segment income before income taxes

 

 

842

 

 

 

934

 

 

 

(92

)

 

Income tax expense

 

 

159

 

 

 

170

 

 

 

(11

)

 

Segment income

 

$

683

 

 

$

764

 

 

$

(81

)

 

 

 

 

 

 

 

 

 

Combined ratio

 

 

96.2

%

 

 

93.3

%

 

 

2.9

 

pts

Impact on combined ratio

 

 

 

 

 

 

 

Net favorable prior year reserve development

 

 

(1.3

)

pts

 

 

pts

 

(1.3

)

pts

Catastrophes, net of reinsurance

 

 

9.3

 

pts

 

4.1

 

pts

 

5.2

 

pts

Underlying combined ratio

 

 

88.2

%

 

 

89.2

%

 

 

(1.0

)

pts

 

 

 

 

 

 

 

 

Net written premiums by market

 

 

 

 

 

 

 

Domestic

 

 

 

 

 

 

 

Select Accounts

 

$

976

 

 

$

974

 

 

 

%

 

Middle Market

 

 

3,166

 

 

 

3,213

 

 

 

(1

)

 

National Accounts

 

 

312

 

 

 

327

 

 

 

(5

)

 

National Property and Other

 

 

720

 

 

 

642

 

 

 

12

 

 

Total Domestic

 

 

5,174

 

 

 

5,156

 

 

 

 

 

International

 

 

524

 

 

 

440

 

 

 

19

 

 

Total

 

$

5,698

 

 

$

5,596

 

 

 

2

%

 

First Quarter 2025 Results

(All comparisons vs. first quarter 2024, unless noted otherwise)

Segment income for Business Insurance was $683 million after-tax, a decrease of $81 million. Segment income decreased primarily due to higher catastrophe losses, partially offset by a higher underlying underwriting gain, net favorable prior year reserve development compared to no net prior year reserve development in the prior year quarter and higher net investment income. The underlying underwriting gain benefited from higher business volumes.

Combined ratio:

  • The combined ratio of 96.2% increased 2.9 points due to higher catastrophe losses (5.2 points), partially offset by net favorable prior year reserve development compared to no net prior year reserve development in the prior year quarter (1.3 points) and an improvement in the underlying combined ratio (1.0 points).
  • The underlying combined ratio improved 1.0 points to an excellent 88.2%.
  • Net favorable prior year reserve development was primarily driven by better than expected loss experience in the workers’ compensation product line for multiple accident years.

Net written premiums of $5.698 billion increased 2%, after the ceded premium impact of the enhanced casualty reinsurance program that took effect January 1, 2025. As the Company previewed, this change in reinsurance reduced the segment’s net written premium growth in the quarter by 4 points, as the full year’s worth of ceded premium was booked in the first quarter. Premium growth in the quarter also reflected strong renewal premium change and retention.

Bond & Specialty Insurance Segment Financial Results

 

 

Three Months Ended March 31,

 

($ in millions and pre-tax, unless noted otherwise)

 

2025

 

2024

 

Change

 

Underwriting gain:

 

$

170

 

 

$

144

 

 

$

26

 

 

Underwriting gain includes:

 

 

 

 

 

 

 

Net favorable prior year reserve development

 

 

67

 

 

 

24

 

 

 

43

 

 

Catastrophes, net of reinsurance

 

 

(19

)

 

 

(5

)

 

 

(14

)

 

Net investment income

 

 

102

 

 

 

90

 

 

 

12

 

 

Other income

 

 

5

 

 

 

6

 

 

 

(1

)

 

Segment income before income taxes

 

 

277

 

 

 

240

 

 

 

37

 

 

Income tax expense

 

 

57

 

 

 

45

 

 

 

12

 

 

Segment income

 

$

220

 

 

$

195

 

 

$

25

 

 

 

 

 

 

 

 

 

 

Combined ratio

 

 

82.5

%

 

 

84.5

%

 

 

(2.0

)

pts

Impact on combined ratio

 

 

 

 

 

 

 

Net favorable prior year reserve development

 

 

(6.7

)

pts

 

(2.5

)

pts

 

(4.2

)

pts

Catastrophes, net of reinsurance

 

 

1.9

 

pts

 

0.5

 

pts

 

1.4

 

pts

Underlying combined ratio

 

 

87.3

%

 

 

86.5

%

 

 

0.8

 

pts

 

 

 

 

 

 

 

 

Net written premiums

 

 

 

 

 

 

 

Domestic

 

 

 

 

 

 

 

Management Liability

 

$

553

 

 

$

543

 

 

 

2

%

 

Surety

 

 

333

 

 

 

296

 

 

 

13

 

 

Total Domestic

 

 

886

 

 

 

839

 

 

 

6

 

 

International

 

 

113

 

 

 

104

 

 

 

9

 

 

Total

 

$

999

 

 

$

943

 

 

 

6

%

 

First Quarter 2025 Results

(All comparisons vs. first quarter 2024, unless noted otherwise)

Segment income for Bond & Specialty Insurance was $220 million after-tax, an increase of $25 million. Segment income increased primarily due to higher net favorable prior year reserve development and higher net investment income, partially offset by higher catastrophe losses and a slightly lower underlying underwriting gain. The underlying underwriting gain benefited from higher business volumes.

Combined ratio:

  • The combined ratio of 82.5% improved 2.0 points due to higher net favorable prior year reserve development (4.2 points), partially offset by higher catastrophe losses (1.4 points) and a higher underlying combined ratio (0.8 points).
  • The underlying combined ratio increased 0.8 points to a very strong 87.3%.
  • Net favorable prior year reserve development was primarily driven by better than expected loss experience in the general liability product line for management liability coverages for multiple accident years and in the fidelity and surety product lines for recent accident years.

Net written premiums of $999 million increased 6%, reflecting production growth in both surety and management liability.

Personal Insurance Segment Financial Results

 

 

Three Months Ended March 31,

 

($ in millions and pre-tax, unless noted otherwise)

 

2025

 

2024

 

Change

 

Underwriting gain (loss):

 

$

(670

)

 

$

99

 

 

$

(769

)

 

Underwriting gain (loss) includes:

 

 

 

 

 

 

 

Net favorable prior year reserve development

 

 

237

 

 

 

67

 

 

 

170

 

 

Catastrophes, net of reinsurance

 

 

(1,738

)

 

 

(498

)

 

 

(1,240

)

 

Net investment income

 

 

172

 

 

 

147

 

 

 

25

 

 

Other income

 

 

18

 

 

 

21

 

 

 

(3

)

 

Segment income (loss) before income taxes

 

 

(480

)

 

 

267

 

 

 

(747

)

 

Income tax expense (benefit)

 

 

(106

)

 

 

47

 

 

 

(153

)

 

Segment income (loss)

 

$

(374

)

 

$

220

 

 

$

(594

)

 

 

 

 

 

 

 

 

 

Combined ratio

 

 

115.2

%

 

 

96.9

%

 

 

18.3

 

pts

Impact on combined ratio

 

 

 

 

 

 

 

Net favorable prior year reserve development

 

 

(5.6

)

pts

 

(1.6

)

pts

 

(4.0

)

pts

Catastrophes, net of reinsurance

 

 

40.9

 

pts

 

12.4

 

pts

 

28.5

 

pts

Underlying combined ratio

 

 

79.9

%

 

 

86.1

%

 

 

(6.2

)

pts

 

 

 

 

 

 

 

 

Net written premiums

 

 

 

 

 

 

 

Domestic

 

 

 

 

 

 

 

Automobile

 

$

1,859

 

 

$

1,859

 

 

 

%

 

Homeowners and Other

 

 

1,813

 

 

 

1,635

 

 

 

11

 

 

Total Domestic

 

 

3,672

 

 

 

3,494

 

 

 

5

 

 

International

 

 

146

 

 

 

149

 

 

 

(2

)

 

Total

 

$

3,818

 

 

$

3,643

 

 

 

5

%

 

First Quarter 2025 Results

(All comparisons vs. first quarter 2024, unless noted otherwise)

Segment loss for Personal Insurance was $374 million after-tax, compared with segment income of $220 million after-tax in the prior year quarter. The difference was primarily due to higher catastrophe losses, partially offset by a higher underlying underwriting gain, higher net favorable prior year reserve development and higher net investment income. The underlying underwriting gain benefited from higher business volumes.

Combined ratio:

  • The combined ratio of 115.2% increased 18.3 points due to higher catastrophe losses (28.5 points), partially offset by an improvement in the underlying combined ratio (6.2 points) and higher net favorable prior year reserve development (4.0 points).
  • The underlying combined ratio of 79.9% improved 6.2 points, reflecting improvement in both Automobile and Homeowners and Other.
  • Net favorable prior year reserve development was primarily driven by better than expected loss experience in both the Automobile and Homeowners and Other product lines for recent accident years.

Net written premiums of $3.818 billion increased 5%, reflecting strong renewal premium change.

Financial Supplement and Conference Call

The information in this press release should be read in conjunction with the financial supplement that is available on our website at Travelers.com. Travelers management will discuss the contents of this release and other relevant topics via webcast at 9 a.m. Eastern (8 a.m. Central) on Wednesday, April 16, 2025. Investors can access the call via webcast at investor.travelers.com or by dialing 1.888.440.6281 within the United States or 1.646.960.0218 outside the United States. Prior to the webcast, a slide presentation pertaining to the quarterly earnings will be available on the Company’s website.

Following the live event, replays will be available via webcast for one year at investor.travelers.com and by telephone for 30 days by dialing 1.800.770.2030 within the United States or 1.647.362.9199 outside the United States. All callers should use conference ID 5449478.

About Travelers

The Travelers Companies, Inc. (NYSE: TRV) is a leading provider of property casualty insurance for auto, home and business. A component of the Dow Jones Industrial Average, Travelers has more than 30,000 employees and generated revenues of more than $46 billion in 2024. For more information, visit Travelers.com.

Travelers may use its website and/or social media outlets, such as Facebook and X, as distribution channels of material Company information. Financial and other important information regarding the Company is routinely accessible through and posted on our website at investor.travelers.com, our Facebook page at facebook.com/travelers and our X account (@Travelers) at x.com/travelers. In addition, you may automatically receive email alerts and other information about Travelers when you enroll your email address by visiting the Email Notifications section at investor.travelers.com.

Travelers is organized into the following reportable business segments:

Business Insurance – Business Insurance offers a broad array of property and casualty insurance products and services to its customers, primarily in the United States, as well as in Canada, the United Kingdom, the Republic of Ireland and throughout other parts of the world, including as a corporate member of Lloyd’s.

Bond & Specialty Insurance – Bond & Specialty Insurance offers surety, fidelity, management liability, professional liability, and other property and casualty coverages and related risk management services to its customers, primarily in the United States, and certain surety and specialty insurance products in Canada, the United Kingdom and the Republic of Ireland, as well as Brazil through a joint venture, in each case utilizing various degrees of financially-based underwriting approaches.

Personal Insurance – Personal Insurance offers a broad range of property and casualty insurance products and services covering individuals’ personal risks, primarily in the United States, as well as in Canada. Personal Insurance’s primary products of automobile and homeowners insurance are complemented by a broad suite of related coverages.

* * * * *

Forward-Looking Statements

This press release contains, and management may make, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, may be forward-looking statements. Words such as “may,” “will,” “should,” “likely,” “probably,” “anticipates,” “expects,” “intends,” “plans,” “projects,” “believes,” “views,” “ensures,” “estimates” and similar expressions are used to identify these forward-looking statements. These statements include, among other things, the Company’s statements about:

  • the Company’s outlook, the impact of trends on its business and its future results of operations and financial condition;
  • the impact of legislative or regulatory actions or court decisions;
  • share repurchase plans;
  • future pension plan contributions;
  • the sufficiency of the Company’s reserves, including asbestos;
  • the impact of emerging claims issues as well as other insurance and non-insurance litigation;
  • the cost and availability of reinsurance coverage;
  • catastrophe losses (including the January 2025 California wildfires) and modeling;
  • the impact of investment, economic and underwriting market conditions, including interest rates, the impact of tariffs and inflation;
  • the Company’s approach to managing its investment portfolio;
  • the impact of changing climate conditions;
  • strategic and operational initiatives to improve growth, profitability and competitiveness;
  • the Company’s competitive advantages and innovation agenda, including executing on that agenda with respect to artificial intelligence;
  • the Company’s cybersecurity policies and practices;
  • new product offerings;
  • the impact of developments in the tort environment; and
  • the impact of developments in the geopolitical environment.

The Company cautions investors that such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

Some of the factors that could cause actual results to differ include, but are not limited to, the following:

Insurance-Related Risks

  • high levels of catastrophe losses;
  • actual claims may exceed the Company’s claims and claim adjustment expense reserves, the estimated level of claims and claim adjustment expense reserves may increase, or increases in loss costs may not be offset with sufficient price increases, including as a result of, among other things, changes in the legal/tort, regulatory and economic environments, including increased inflation and the impact of tariffs;
  • the Company’s continued exposure to asbestos and environmental claims and related litigation;
  • the Company is exposed to, and may face adverse developments involving, mass tort claims; and
  • the effects of emerging claim and coverage issues on the Company’s business are uncertain, and court decisions or legislative changes that take place after the Company issues its policies can result in an unexpected increase in the number of claims.

Financial, Economic and Credit Risks

  • a period of financial market disruption or an economic downturn;
  • the Company’s investment portfolio is subject to credit and interest rate risk, and may suffer reduced or low returns or material realized or unrealized losses;
  • the Company is exposed to credit risk related to reinsurance and structured settlements, and reinsurance coverage may not be available to the Company;
  • the Company is exposed to credit risk in certain of its insurance operations and with respect to certain guarantee or indemnification arrangements that it has with third parties;
  • a downgrade in the Company’s claims-paying and financial strength ratings; and
  • the Company’s insurance subsidiaries may be unable to pay dividends to the Company’s holding company in sufficient amounts.

Business and Operational Risks

  • the intense competition that the Company faces, including with respect to attracting and retaining employees, and the impact of innovation, technological change and changing customer preferences on the insurance industry and the markets in which it operates;
  • disruptions to the Company’s relationships with its independent agents and brokers or the Company’s inability to manage effectively a changing distribution landscape;
  • the Company’s efforts to develop new products or services, expand in targeted markets, improve business processes and workflows or make acquisitions may not be successful and may create enhanced risks;
  • the Company’s pricing and capital models may provide materially different indications than actual results;
  • loss of or significant restrictions on the use of particular types of underwriting criteria, such as credit scoring, or other data or methodologies, in the pricing and underwriting of the Company’s products;
  • the Company is subject to additional risks associated with its business outside the United States; and
  • future pandemics (including new variants of COVID-19).

Technology and Intellectual Property Risks

  • as a result of cyber attacks (the risk of which could be exacerbated by geopolitical tensions) or otherwise, the Company may experience difficulties with technology, data and network security or outsourcing relationships;
  • the Company’s dependence on effective information technology systems and on continuing to develop and implement improvements in technology, including with respect to artificial intelligence; and
  • the Company may be unable to protect and enforce its own intellectual property or may be subject to claims for infringing the intellectual property of others.

Regulatory and Compliance Risks

  • changes in regulation, including changes in tax laws; and
  • the Company’s compliance controls may not be effective.

In addition, the Company’s share repurchase plans depend on a variety of factors, including the Company’s financial position, earnings, share price, catastrophe losses, maintaining capital levels appropriate for the Company’s business operations, changes in levels of written premiums, funding of the Company’s qualified pension plan, capital requirements of the Company’s operating subsidiaries, legal requirements, regulatory constraints, other investment opportunities (including mergers and acquisitions and related financings), market conditions, changes in tax laws and other factors.

Our forward-looking statements speak only as of the date of this press release or as of the date they are made, and we undertake no obligation to update forward-looking statements. For a more detailed discussion of these factors, see the information under the captions “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Forward Looking Statements” in the quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on April 16, 2025, and in our most recent annual report on Form 10-K filed with the SEC on February 13, 2025, in each case as updated by our periodic filings with the SEC.

GLOSSARY OF FINANCIAL MEASURES AND RECONCILIATIONS OF GAAP MEASURES TO NON-GAAP MEASURES

The following measures are used by the Company’s management to evaluate financial performance against historical results, to establish performance targets on a consolidated basis and for other reasons as discussed below. In some cases, these measures are considered non-GAAP financial measures under applicable SEC rules because they are not displayed as separate line items in the consolidated financial statements or are not required to be disclosed in the notes to financial statements or, in some cases, include or exclude certain items not ordinarily included or excluded in the most comparable GAAP financial measure. Reconciliations of these measures to the most comparable GAAP measures also follow.

In the opinion of the Company’s management, a discussion of these measures provides investors, financial analysts, rating agencies and other financial statement users with a better understanding of the significant factors that comprise the Company’s periodic results of operations and how management evaluates the Company’s financial performance.

Some of these measures exclude net realized investment gains (losses), net of tax, and/or net unrealized investment gains (losses), net of tax, included in shareholders’ equity, which can be significantly impacted by both discretionary and other economic factors and are not necessarily indicative of operating trends.

Other companies may calculate these measures differently, and, therefore, their measures may not be comparable to those used by the Company’s management.

RECONCILIATION OF NET INCOME TO CORE INCOME AND CERTAIN OTHER NON-GAAP MEASURES

Core income (loss) is consolidated net income (loss) excluding the after-tax impact of net realized investment gains (losses), discontinued operations, the effect of a change in tax laws and tax rates at enactment, and cumulative effect of changes in accounting principles when applicable. Segment income (loss) is determined in the same manner as core income (loss) on a segment basis. Management uses segment income (loss) to analyze each segment’s performance and as a tool in making business decisions. Financial statement users also consider core income (loss) when analyzing the results and trends of insurance companies. Core income (loss) per share is core income (loss) on a per common share basis.

Reconciliation of Net Income to Core Income less Preferred Dividends

 

 

Three Months Ended

March 31,

 

Twelve Months Ended

March 31,

($ in millions, after-tax)

 

2025

 

2024

 

2025

 

2024

Net income

 

$

395

 

$

1,123

 

 

$

4,271

 

$

3,140

Adjustments:

 

 

 

 

 

 

 

 

Net realized investment (gains) losses

 

 

48

 

 

(27

)

 

 

101

 

 

57

Core income

 

$

443

 

$

1,096

 

 

$

4,372

 

$

3,197

 

 

Three Months Ended

March 31,

($ in millions, pre-tax)

 

2025

 

2024

Net income

 

$

468

 

$

1,370

 

Adjustments:

 

 

 

 

Net realized investment (gains) losses

 

 

61

 

 

(35

)

Core income

 

$

529

 

$

1,335

 

 

 

Twelve Months Ended December 31,

 

 

Average

Annual

($ in millions, after-tax)

 

2024

 

2023

 

2022

 

2021

 

2020

 

 

2005 – 2019

Net income

 

$

4,999

 

$

2,991

 

$

2,842

 

$

3,662

 

 

$

2,697

 

 

 

$

3,007

 

Less: Loss from discontinued operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(29

)

Income from continuing operations

 

 

4,999

 

 

2,991

 

 

2,842

 

 

3,662

 

 

 

2,697

 

 

 

 

3,036

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

Net realized investment (gains) losses

 

 

26

 

 

81

 

 

156

 

 

(132

)

 

 

(11

)

 

 

 

(44

)

Impact of changes in tax laws and/or tax rates (1) (2)

 

 

 

 

 

 

 

 

(8

)

 

 

 

 

 

 

9

 

Core income

 

 

5,025

 

 

3,072

 

 

2,998

 

 

3,522

 

 

 

2,686

 

 

 

 

3,001

 

Less: Preferred dividends

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2

 

Core income, less preferred dividends

 

$

5,025

 

$

3,072

 

$

2,998

 

$

3,522

 

 

$

2,686

 

 

 

$

2,999

 

(1) Impact is recognized in the accounting period in which the change is enacted

(2) 2017 reflects impact of Tax Cuts and Jobs Act of 2017 (TCJA)

Reconciliation of Net Income per Share to Core Income per Share on a Diluted Basis

 

 

Three Months Ended

March 31,

 

 

2025

 

2024

Diluted income per share

 

 

 

 

Net income

 

$

1.70

 

$

4.80

 

Adjustments:

 

 

 

 

Net realized investment (gains) losses, after-tax

 

 

0.21

 

 

(0.11

)

Core income

 

$

1.91

 

$

4.69

 

Reconciliation of Segment Income (Loss) to Total Core Income

 

 

Three Months Ended

March 31,

($ in millions, after-tax)

 

2025

 

2024

Business Insurance

 

$

683

 

 

$

764

 

Bond & Specialty Insurance

 

 

220

 

 

 

195

 

Personal Insurance

 

 

(374

)

 

 

220

 

Total segment income (loss)

 

 

529

 

 

 

1,179

 

Interest Expense and Other

 

 

(86

)

 

 

(83

)

Total core income

 

$

443

 

 

$

1,096

 

RECONCILIATION OF SHAREHOLDERS’ EQUITY TO ADJUSTED SHAREHOLDERS’ EQUITY AND CALCULATION OF RETURN ON EQUITY AND CORE RETURN ON EQUITY

Adjusted shareholders’ equity is shareholders’ equity excluding net unrealized investment gains (losses), net of tax, included in shareholders’ equity, net realized investment gains (losses), net of tax, for the period presented, the effect of a change in tax laws and tax rates at enactment (excluding the portion related to net unrealized investment gains (losses)), preferred stock and discontinued operations.

Reconciliation of Shareholders’ Equity to Adjusted Shareholders’ Equity

 

 

As of March 31,

($ in millions)

 

2025

 

2024

Shareholders’ equity

 

$

28,191

 

$

25,022

 

Adjustments:

 

 

 

 

Net unrealized investment losses, net of tax, included in shareholders’ equity

 

 

3,299

 

 

3,721

 

Net realized investment (gains) losses, net of tax

 

 

48

 

 

(27

)

Adjusted shareholders’ equity

 

$

31,538

 

$

28,716

 

 

 

As of December 31,

 

 

Average

Annual

($ in millions)

 

2024

 

2023

 

2022

 

2021

 

2020

 

 

2005 – 2019

Shareholders’ equity

 

$

27,864

 

$

24,921

 

$

21,560

 

$

28,887

 

 

$

29,201

 

 

 

$

24,744

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

Net unrealized investment (gains) losses, net of tax, included in shareholders’ equity

 

 

3,640

 

 

3,129

 

 

4,898

 

 

(2,415

)

 

 

(4,074

)

 

 

 

(1,300

)

Net realized investment (gains) losses, net of tax

 

 

26

 

 

81

 

 

156

 

 

(132

)

 

 

(11

)

 

 

 

(44

)

Impact of changes in tax laws and/or tax rates (1) (2)

 

 

 

 

 

 

 

 

(8

)

 

 

 

 

 

 

19

 

Preferred stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(42

)

Loss from discontinued operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

29

 

Adjusted shareholders’ equity

 

$

31,530

 

$

28,131

 

$

26,614

 

$

26,332

 

 

$

25,116

 

 

 

$

23,406

 

(1) Impact is recognized in the accounting period in which the change is enacted

(2) 2017 reflects impact of Tax Cuts and Jobs Act of 2017 (TCJA)

Return on equity is the ratio of annualized net income (loss) less preferred dividends to average shareholders’ equity for the periods presented. Core return on equity is the ratio of annualized core income (loss) less preferred dividends to adjusted average shareholders’ equity for the periods presented. In the opinion of the Company’s management, these are important indicators of how well management creates value for its shareholders through its operating activities and its capital management.

Average shareholders’ equity is (a) the sum of total shareholders’ equity excluding preferred stock at the beginning and end of each of the quarters for the period presented divided by (b) the number of quarters in the period presented times two. Adjusted average shareholders’ equity is (a) the sum of total adjusted shareholders’ equity at the beginning and end of each of the quarters for the period presented divided by (b) the number of quarters in the period presented times two.

Calculation of Return on Equity and Core Return on Equity

 

 

Three Months Ended

March 31,

 

Twelve Months Ended

March 31,

($ in millions, after-tax)

 

2025

 

2024

 

2025

 

2024

Annualized net income

 

$

1,580

 

 

$

4,493

 

 

$

4,271

 

 

$

3,140

 

Average shareholders’ equity

 

 

28,027

 

 

 

24,972

 

 

 

26,757

 

 

 

22,698

 

Return on equity

 

 

5.6

%

 

 

18.0

%

 

 

16.0

%

 

 

13.8

%

Annualized core income

 

$

1,773

 

 

$

4,384

 

 

$

4,372

 

 

$

3,197

 

Adjusted average shareholders’ equity

 

 

31,521

 

 

 

28,383

 

 

 

30,079

 

 

 

27,197

 

Core return on equity

 

 

5.6

%

 

 

15.4

%

 

 

14.5

%

 

 

11.8

%

 

 

Twelve Months Ended

December 31,

 

 

Average

Annual

($ in millions, after-tax)

 

2024

 

2023

 

2022

 

2021

 

2020

 

 

2005 – 2019

Net income, less preferred dividends

 

$

4,999

 

 

$

2,991

 

 

$

2,842

 

 

$

3,662

 

 

$

2,697

 

 

 

$

3,005

 

Average shareholders’ equity

 

 

25,993

 

 

 

22,031

 

 

 

23,384

 

 

 

28,735

 

 

 

26,892

 

 

 

 

24,693

 

Return on equity

 

 

19.2

%

 

 

13.6

%

 

 

12.2

%

 

 

12.7

%

 

 

10.0

%

 

 

 

12.2

%

Core income, less preferred dividends

 

$

5,025

 

 

$

3,072

 

 

$

2,998

 

 

$

3,522

 

 

$

2,686

 

 

 

$

2,999

 

Adjusted average shareholders’ equity

 

 

29,295

 

 

 

26,772

 

 

 

26,588

 

 

 

25,718

 

 

 

23,790

 

 

 

 

23,397

 

Core return on equity

 

 

17.2

%

 

 

11.5

%

 

 

11.3

%

 

 

13.7

%

 

 

11.3

%

 

 

 

12.8

%

RECONCILIATION OF NET INCOME TO UNDERWRITING GAIN EXCLUDING CERTAIN ITEMS

Underwriting gain (loss) is net earned premiums and fee income less claims and claim adjustment expenses and insurance-related expenses. In the opinion of the Company’s management, it is important to measure the profitability of each segment excluding the results of investing activities, which are managed separately from the insurance business. This measure is used to assess each segment’s business performance and as a tool in making business decisions. Underwriting gain, excluding the impact of catastrophes and net favorable (unfavorable) prior year loss reserve development,is the underwriting gain adjusted to exclude claims and claim adjustment expenses, reinstatement premiums and assessments related to catastrophes and loss reserve development related to time periods prior to the current year. In the opinion of the Company’s management, this measure is meaningful to users of the financial statements to understand the Company’s periodic earnings and the variability of earnings caused by the unpredictable nature (i.e., the timing and amount) of catastrophes and loss reserve development. This measure is also referred to as underlying underwriting gain, underlying underwriting margin,underlying underwriting income or underlying underwriting result.

A catastrophe is a severe loss designated, or reasonably expected by the Company to be designated, a catastrophe by one or more industry recognized organizations that track and report on insured losses resulting from catastrophic events, such as Property Claim Services (PCS) for events in the United States and Canada. Catastrophes can be caused by various natural events, including, among others, hurricanes, tornadoes and other windstorms, earthquakes, hail, wildfires, severe winter weather, floods, tsunamis, volcanic eruptions and other naturally-occurring events, such as solar flares. Catastrophes can also be man-made, such as terrorist attacks and other intentionally or unintentionally destructive acts, including those involving nuclear, biological, chemical and radiological events, cyber events, explosions and destruction of infrastructure. Each catastrophe has unique characteristics and catastrophes are not predictable as to timing or amount. Their effects are included in net and core income (loss) and claims and claim adjustment expense reserves upon occurrence. A catastrophe may result in the payment of reinsurance reinstatement premiums and assessments from various pools.

The Company’s threshold for disclosing catastrophes is primarily determined at the reportable segment level. If a threshold for one segment or a combination thereof is reached and the other segments have losses from the same event, losses from the event are identified as catastrophe losses in the segment results and for the consolidated results of the Company. Additionally, an aggregate threshold is applied for international business across all reportable segments. The threshold for 2025 ranges from $20 million to $30 million of losses before reinsurance and taxes.

Net favorable (unfavorable) prior year loss reserve development is the increase or decrease in incurred claims and claim adjustment expenses as a result of the re-estimation of claims and claim adjustment expense reserves at successive valuation dates for a given group of claims, which may be related to one or more prior years. In the opinion of the Company’s management, a discussion of loss reserve development is meaningful to users of the financial statements as it allows them to assess the impact between prior and current year development on incurred claims and claim adjustment expenses, net and core income (loss), and changes in claims and claim adjustment expense reserve levels from period to period.

Reconciliation of Net Income to Pre-Tax Underlying Underwriting Income (also known as Underlying Underwriting Gain)

 

 

Three Months Ended

March 31,

($ in millions, after-tax, except as noted)

 

2025

 

2024

Net income

 

$

395

 

 

$

1,123

 

Net realized investment (gains) losses

 

 

48

 

 

 

(27

)

Core income

 

 

443

 

 

 

1,096

 

Net investment income

 

 

(763

)

 

 

(698

)

Other (income) expense, including interest expense

 

 

81

 

 

 

74

 

Underwriting income (loss)

 

 

(239

)

 

 

472

 

Income tax expense (benefit) on underwriting results

 

 

(66

)

 

 

105

 

Pre-tax underwriting income (loss)

 

 

(305

)

 

 

577

 

Pre-tax impact of net favorable prior year reserve development

 

 

(378

)

 

 

(91

)

Pre-tax impact of catastrophes

 

 

2,266

 

 

 

712

 

Pre-tax underlying underwriting income

 

$

1,583

 

 

$

1,198

 

Reconciliation of Net Income to After-Tax Underlying Underwriting Income (also known as Underlying Underwriting Gain)

 

 

Three Months Ended

March 31,

($ in millions, after-tax)

 

2025

 

2024

Net income

 

$

395

 

 

$

1,123

 

Net realized investment (gains) losses

 

 

48

 

 

 

(27

)

Core income

 

 

443

 

 

 

1,096

 

Net investment income

 

 

(763

)

 

 

(698

)

Other (income) expense, including interest expense

 

 

81

 

 

 

74

 

Underwriting income (loss)

 

 

(239

)

 

 

472

 

Impact of net favorable prior year reserve development

 

 

(297

)

 

 

(71

)

Impact of catastrophes

 

 

1,790

 

 

 

563

 

Underlying underwriting income

 

$

1,254

 

 

$

964

 

 

 

Twelve Months Ended December 31,

($ in millions, after-tax)

 

2024

 

2023

 

2022

 

2021

 

2020

 

2019

 

2018

 

2017

 

2016

 

2015

 

2014

 

2013

 

2012

Net income

 

$

4,999

 

 

$

2,991

 

 

$

2,842

 

 

$

3,662

 

 

$

2,697

 

 

$

2,622

 

 

$

2,523

 

 

$

2,056

 

 

$

3,014

 

 

$

3,439

 

 

$

3,692

 

 

$

3,673

 

 

$

2,473

 

Net realized investment (gains) losses

 

 

26

 

 

 

81

 

 

 

156

 

 

 

(132

)

 

 

(11

)

 

 

(85

)

 

 

(93

)

 

 

(142

)

 

 

(47

)

 

 

(2

)

 

 

(51

)

 

 

(106

)

 

 

(32

)

Impact of changes in tax laws and/or tax rates (1) (2)

 

 

 

 

 

 

 

 

 

 

 

(8

)

 

 

 

 

 

 

 

 

 

 

 

129

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Core income

 

 

5,025

 

 

 

3,072

 

 

 

2,998

 

 

 

3,522

 

 

 

2,686

 

 

 

2,537

 

 

 

2,430

 

 

 

2,043

 

 

 

2,967

 

 

 

3,437

 

 

 

3,641

 

 

 

3,567

 

 

 

2,441

 

Net investment income

 

 

(2,952

)

 

 

(2,436

)

 

 

(2,170

)

 

 

(2,541

)

 

 

(1,908

)

 

 

(2,097

)

 

 

(2,102

)

 

 

(1,872

)

 

 

(1,846

)

 

 

(1,905

)

 

 

(2,216

)

 

 

(2,186

)

 

 

(2,316

)

Other (income) expense, including interest expense

 

 

308

 

 

 

337

 

 

 

277

 

 

 

235

 

 

 

232

 

 

 

214

 

 

 

248

 

 

 

179

 

 

 

78

 

 

 

193

 

 

 

159

 

 

 

61

 

 

 

171

 

Underwriting income

 

 

2,381

 

 

 

973

 

 

 

1,105

 

 

 

1,216

 

 

 

1,010

 

 

 

654

 

 

 

576

 

 

 

350

 

 

 

1,199

 

 

 

1,725

 

 

 

1,584

 

 

 

1,442

 

 

 

296

 

Impact of net (favorable) unfavorable prior year reserve development

 

 

(559

)

 

 

(113

)

 

 

(512

)

 

 

(424

)

 

 

(276

)

 

 

47

 

 

 

(409

)

 

 

(378

)

 

 

(510

)

 

 

(617

)

 

 

(616

)

 

 

(552

)

 

 

(622

)

Impact of catastrophes

 

 

2,632

 

 

 

2,361

 

 

 

1,480

 

 

 

1,459

 

 

 

1,274

 

 

 

699

 

 

 

1,355

 

 

 

1,267

 

 

 

576

 

 

 

338

 

 

 

462

 

 

 

387

 

 

 

1,214

 

Underlying underwriting income

 

$

4,454

 

 

$

3,221

 

 

$

2,073

 

 

$

2,251

 

 

$

2,008

 

 

$

1,400

 

 

$

1,522

 

 

$

1,239

 

 

$

1,265

 

 

$

1,446

 

 

$

1,430

 

 

$

1,277

 

 

$

888

 

(1) Impact is recognized in the accounting period in which the change is enacted

(2) 2017 reflects impact of Tax Cuts and Jobs Act of 2017 (TCJA)

COMBINED RATIO AND ADJUSTMENTS FOR UNDERLYING COMBINED RATIO

Combined ratio: For Statutory Accounting Practices (SAP), the combined ratio is the sum of the SAP loss and LAE ratio and the SAP underwriting expense ratio as defined in the statutory financial statements required by insurance regulators. The combined ratio, as used in this earnings release, is the equivalent of, and is calculated in the same manner as, the SAP combined ratio except that the SAP underwriting expense ratio is based on net written premiums and the underwriting expense ratio as used in this earnings release is based on net earned premiums.

For SAP, the loss and LAE ratio is the ratio of incurred losses and loss adjustment expenses less certain administrative services fee income to net earned premiums as defined in the statutory financial statements required by insurance regulators. The loss and LAE ratio as used in this earnings release is calculated in the same manner as the SAP ratio.

For SAP, the underwriting expense ratio is the ratio of underwriting expenses incurred (including commissions paid), less certain administrative services fee income and billing and policy fees and other, to net written premiums as defined in the statutory financial statements required by insurance regulators. The underwriting expense ratio as used in this earnings release, is the ratio of underwriting expenses (including the amortization of deferred acquisition costs), less certain administrative services fee income, billing and policy fees and other, to net earned premiums.

The combined ratio, loss and LAE ratio, and underwriting expense ratio are used as indicators of the Company’s underwriting discipline, efficiency in acquiring and servicing its business and overall underwriting profitability. A combined ratio under 100% generally indicates an underwriting profit. A combined ratio over 100% generally indicates an underwriting loss.

Underlying combined ratio represents the combined ratio excluding the impact of net prior year reserve development and catastrophes. The underlying combined ratio is an indicator of the Company’s underwriting discipline and underwriting profitability for the current accident year.

Other companies’ method of computing similarly titled measures may not be comparable to the Company’s method of computing these ratios.

Calculation of the Combined Ratio

 

 

Three Months Ended

March 31,

($ in millions, pre-tax)

 

2025

 

2024

Loss and loss adjustment expense ratio

 

 

 

 

Claims and claim adjustment expenses

 

$

8,006

 

 

$

6,656

 

Less:

 

 

 

 

Policyholder dividends

 

 

13

 

 

 

12

 

Allocated fee income

 

 

45

 

 

 

39

 

Loss ratio numerator

 

$

7,948

 

 

$

6,605

 

Underwriting expense ratio

 

 

 

 

Amortization of deferred acquisition costs

 

$

1,778

 

 

$

1,698

 

General and administrative expenses (G&A)

 

 

1,459

 

 

 

1,406

 

Less:

 

 

 

 

Non-insurance G&A

 

 

109

 

 

 

102

 

Allocated fee income

 

 

74

 

 

 

70

 

Billing and policy fees and other

 

 

28

 

 

 

30

 

Expense ratio numerator

 

$

3,026

 

 

$

2,902

 

Earned premium

 

$

10,710

 

 

$

10,126

 

Combined ratio (1)

 

 

 

 

Loss and loss adjustment expense ratio

 

 

74.2

%

 

 

65.2

%

Underwriting expense ratio

 

 

28.3

%

 

 

28.7

%

Combined ratio

 

 

102.5

%

 

 

93.9

%

Impact on combined ratio:

 

 

 

 

Net favorable prior year reserve development

 

 

(3.5

)%

 

 

(0.9

)%

Catastrophes, net of reinsurance

 

 

21.2

%

 

 

7.1

%

Underlying combined ratio

 

 

84.8

%

 

 

87.7

%

(1) For purposes of computing ratios, billing and policy fees and other (which are a component of other revenues) are allocated as a reduction of underwriting expenses. In addition, fee income is allocated as a reduction of losses and loss adjustment expenses and underwriting expenses. These allocations are to conform the calculation of the combined ratio with statutory accounting. Additionally, general and administrative expenses include non-insurance expenses that are excluded from underwriting expenses, and accordingly are excluded in calculating the combined ratio.

RECONCILIATION OF BOOK VALUE PER SHARE AND SHAREHOLDERS’ EQUITY TO CERTAIN NON-GAAP MEASURES

Book value per share is total common shareholders’ equity divided by the number of common shares outstanding. Adjusted book value per share is total common shareholders’ equity excluding net unrealized investment gains and losses, net of tax, included in shareholders’ equity, divided by the number of common shares outstanding.In the opinion of the Company’s management, adjusted book value per share is useful in an analysis of a property casualty company’s book value per share as it removes the effect of changing prices on invested assets (i.e., net unrealized investment gains (losses), net of tax), which do not have an equivalent impact on unpaid claims and claim adjustment expense reserves. Tangible book value per share is adjusted book value per share excluding the after-tax value of goodwill and other intangible assets divided by the number of common shares outstanding. In the opinion of the Company’s management, tangible book value per share is useful in an analysis of a property casualty company’s book value on a nominal basis as it removes certain effects of purchase accounting (i.e., goodwill and other intangible assets), in addition to the effect of changing prices on invested assets.

Reconciliation of Shareholders’ Equity to Tangible Shareholders’ Equity, Excluding Net Unrealized Investment Gains (Losses), Net of Tax and Calculation of Book Value Per Share, Adjusted Book Value Per Share and Tangible Book Value Per Share

 

 

As of

($ in millions, except per share amounts)

 

March 31,

2025

 

December 31,

2024

 

March 31,

2024

Shareholders’ equity

 

$

28,191

 

 

$

27,864

 

 

$

25,022

 

Less: Net unrealized investment losses, net of tax, included in shareholders’ equity

 

 

(3,299

)

 

 

(3,640

)

 

 

(3,721

)

Common shareholders’ equity, excluding net unrealized investment losses, net of tax, included in shareholders’ equity

 

 

31,490

 

 

 

31,504

 

 

 

28,743

 

Less:

 

 

 

 

 

 

Goodwill

 

 

4,245

 

 

 

4,233

 

 

 

4,251

 

Other intangible assets

 

 

356

 

 

 

360

 

 

 

376

 

Impact of deferred tax on other intangible assets

 

 

(88

)

 

 

(85

)

 

 

(85

)

Tangible shareholders’ equity, excluding net unrealized investment losses, net of tax, included in shareholders’ equity

 

$

26,977

 

 

$

26,996

 

 

$

24,201

 

Common shares outstanding

 

 

226.6

 

 

 

226.6

 

 

 

229.0

 

Book value per share

 

$

124.43

 

 

$

122.97

 

 

$

109.28

 

Adjusted book value per share

 

 

138.99

 

 

 

139.04

 

 

 

125.53

 

Tangible book value per share, excluding net unrealized investment losses, net of tax, included in shareholders’ equity

 

 

119.07

 

 

 

119.14

 

 

 

105.69

 

RECONCILIATION OF TOTAL CAPITALIZATION TO TOTAL CAPITALIZATION EXCLUDING NET UNREALIZED INVESTMENT GAINS (LOSSES), NET OF TAX

Total capitalization is the sum of total shareholders’ equity and debt. Debt-to-capital ratio excluding net unrealized gains (losses) on investments, net of tax, included in shareholders’ equity,is the ratio of debt to total capitalization excluding the after-tax impact of net unrealized investment gains and losses included in shareholders’ equity. In the opinion of the Company’s management, the debt-to-capital ratio is useful in an analysis of the Company’s financial leverage.

 

 

As of

($ in millions)

 

March 31,

2025

 

December 31,

2024

Debt

 

$

8,033

 

 

$

8,033

 

Shareholders’ equity

 

 

28,191

 

 

 

27,864

 

Total capitalization

 

 

36,224

 

 

 

35,897

 

Less: Net unrealized investment losses, net of tax, included in shareholders’ equity

 

 

(3,299

)

 

 

(3,640

)

Total capitalization excluding net unrealized losses on investments, net of tax, included in shareholders’ equity

 

$

39,523

 

 

$

39,537

 

Debt-to-capital ratio

 

 

22.2

%

 

 

22.4

%

Debt-to-capital ratio excluding net unrealized investment losses, net of tax, included in shareholders’ equity

 

 

20.3

%

 

 

20.3

%

RECONCILIATION OF INVESTED ASSETS TO INVESTED ASSETS EXCLUDING NET UNREALIZED INVESTMENT GAINS (LOSSES)

 

 

As of March 31,

($ in millions)

 

2025

 

2024

Invested assets

 

$

95,696

 

 

$

88,657

 

Less: Net unrealized investment losses, pre-tax

 

 

(4,172

)

 

 

(4,720

)

Invested assets excluding net unrealized investment losses

 

$

99,868

 

 

$

93,377

 

 

 

As of December 31,

($ in millions)

 

2024

 

2023

 

2022

 

2021

 

2020

 

2019

 

2018

 

2017

 

2016

 

2015

 

2014

 

2013

 

2012

Invested assets

 

$

94,223

 

 

$

88,810

 

 

$

80,454

 

 

$

87,375

 

$

84,423

 

$

77,884

 

$

72,278

 

 

$

72,502

 

$

70,488

 

$

70,470

 

$

73,261

 

$

73,160

 

$

73,838

Less: Net unrealized investment gains (losses), pre-tax

 

 

(4,609

)

 

 

(3,970

)

 

 

(6,220

)

 

 

3,060

 

 

5,175

 

 

2,853

 

 

(137

)

 

 

1,414

 

 

1,112

 

 

1,974

 

 

3,008

 

 

2,030

 

 

4,761

Invested assets excluding net unrealized investment gains (losses)

 

$

98,832

 

 

$

92,780

 

 

$

86,674

 

 

$

84,315

 

$

79,248

 

$

75,031

 

$

72,415

 

 

$

71,088

 

$

69,376

 

$

68,496

 

$

70,253

 

$

71,130

 

$

69,077

OTHER DEFINITIONS

Gross written premiums reflect the direct and assumed contractually determined amounts charged to policyholders for the effective period of the contract based on the terms and conditions of the insurance contract. Net written premiums reflect gross written premiums less premiums ceded to reinsurers.

For Business Insurance and Bond & Specialty Insurance, retention is the amount of premium available for renewal that was retained, excluding rate and exposure changes. For Personal Insurance, retention is the ratio of the expected number of renewal policies that will be retained throughout the annual policy period to the number of available renewal base policies. For all of the segments, renewal rate change represents the estimated change in average premium on policies that renew, excluding exposure changes. Exposure is the measure of risk used in the pricing of an insurance product. The change in exposure is the amount of change in premium on policies that renew attributable to the change in portfolio risk. Renewal premium change represents the estimated change in average premium on policies that renew, including rate and exposure changes. New business is the amount of written premium related to new policyholders and additional products sold to existing policyholders. These are operating statistics, which are in part dependent on the use of estimates and are therefore subject to change. For Business Insurance, retention, renewal premium change and new business exclude National Accounts. For Bond & Specialty Insurance, retention, renewal premium change and new business exclude surety and other products that are generally sold on a non-recurring, project specific basis. For each of the segments, production statistics referred to herein are domestic only unless otherwise indicated.

Statutory capital and surplus represents the excess of an insurance company’s admitted assets over its liabilities, including loss reserves, as determined in accordance with statutory accounting practices.

Holding company liquidity is the total funds available at the holding company level to fund general corporate purposes, primarily the payment of shareholder dividends and debt service. These funds consist of total cash, short-term invested assets and other readily marketable securities held by the holding company.

For a glossary of other financial terms used in this press release, we refer you to the Company’s most recent annual report on Form 10-K filed with the SEC on February 13, 2025, and subsequent periodic filings with the SEC.

Media:

Patrick Linehan

917.778.6267

Institutional Investors:

Abbe Goldstein

917.778.6825

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Insurance Professional Services

MEDIA:

Logo
Logo

YieldMax™ ETFs Announces Distributions on TSLY (101.76%), CRSH (100.89%), ULTY (76.45%), LFGY (65.07%), FEAT (61.22%), and Others

CHICAGO, MILWAUKEE and NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) — YieldMax™ today announced distributions for the YieldMax™ Weekly Payers and Group A ETFs listed in the table below.

ETF
Ticker1
ETF Name Distribution Frequency Distribution
per Share
Distribution Rate2,4 30-Day

SEC Yield3
ROC5 Ex-Date & Record
Date
Payment
Date
CHPY YieldMax™ Semiconductor Portfolio Option Income ETF
Weekly
$0.3627 84.42% 4/17/25 4/21/25
GPTY YieldMax™ AI & Tech Portfolio Option Income ETF
Weekly
$0.2545 34.59% 0.00% 63.04% 4/17/25 4/21/25
LFGY YieldMax™ Crypto Industry & Tech Portfolio Option Income ETF
Weekly
$0.4307 65.07% 0.00% 35.49% 4/17/25 4/21/25
QDTY YieldMax™ Nasdaq 100 0DTE Covered Call ETF
Weekly
$0.3320 43.93% 0.00% 100.00% 4/17/25 4/21/25
RDTY YieldMax™ R2000 0DTE Covered Call ETF
Weekly
$0.3745 46.65% 0.00% 100.00% 4/17/25 4/21/25
SDTY YieldMax™ S&P 500 0DTE Covered Call ETF
Weekly
$0.3085 38.91% 0.00% 100.00% 4/17/25 4/21/25
ULTY YieldMax™ Ultra Option Income Strategy ETF
Weekly
$0.0852 76.45% 2.21% 99.18% 4/17/25 4/21/25
YMAG YieldMax™ Magnificent 7 Fund of Option Income ETFs
Weekly
$0.0943 33.85% 69.89% 65.96% 4/17/25 4/21/25
YMAX YieldMax™ Universe Fund
of Option Income ETFs

Weekly
$0.1334 54.00% 96.57% 54.97% 4/17/25 4/21/25
CRSH YieldMax™ Short TSLA Option Income Strategy ETF Every 4 weeks $0.5616 100.89% 1.79% 0.00% 4/17/25 4/21/25
FEAT YieldMax™ Dorsey Wright Featured 5 Income ETF Every 4 weeks $1.6435 61.22% 108.54% 0.00% 4/17/25 4/21/25
FIVY YieldMax™ Dorsey Wright Hybrid 5 Income ETF Every 4 weeks $1.0283 37.65% 69.37% 0.00% 4/17/25 4/21/25
GOOY YieldMax™ GOOGL Option Income Strategy ETF Every 4 weeks $0.3729 40.07% 4.67% 90.74% 4/17/25 4/21/25
OARK YieldMax™ Innovation Option Income Strategy ETF Every 4 weeks $0.2923 51.17% 3.51% 93.61% 4/17/25 4/21/25
SNOY YieldMax™ SNOW Option Income Strategy ETF Every 4 weeks $0.6864 59.94% 3.01% 94.51% 4/17/25 4/21/25
TSLY YieldMax™ TSLA Option Income Strategy ETF Every 4 weeks $0.6598 101.76% 3.87% 96.85% 4/17/25 4/21/25
TSMY YieldMax™ TSM Option Income Strategy ETF Every 4 weeks $0.5635 51.83% 3.61% 16.38% 4/17/25 4/21/25
XOMO YieldMax™ XOM Option Income Strategy ETF Every 4 weeks $0.3500 34.91% 3.18% 90.74% 4/17/25 4/21/25
YBIT YieldMax™ Bitcoin Option Income Strategy ETF Every 4 weeks $0.4110 53.00% 1.52% 30.49% 4/17/25 4/21/25
Weekly Payers & Group B ETFs scheduled for next week: CHPY GPTY LFGY QDTY RDTY SDTY UTLY YMAG YMAX BABO DIPS FBY GDXY JPMO MARO MRNY NVDY PLTY
 

Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted above. Performance current to the most recent month-end can be obtained by calling 
(833) 378-0717
.

Note: DIPS, FIAT,CRSH, YQQQ and WNTR are hereinafter referred to as the “Short ETFs.”

Distributions are not guaranteed. The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs. In particular, future distributions on any ETF may differ significantly from its Distribution Rate or 30-Day SEC Yield. You are not guaranteed a distribution under the ETFs. Distributions for the ETFs (if any) are variable and may vary significantly from period to period and may be zero. Accordingly, the Distribution Rate and 30-Day SEC Yield will change over time, and such change may be significant.

Investors in the Funds will not have rights to receive dividends or other distributions with respect to the underlying reference asset(s).


1

All YieldMax™ ETFs shown in the table above (except YMAX, YMAG, FEAT, FIVY and ULTY) have a gross expense ratio of 0.99%. YMAX, YMAG and FEAT have a Management Fee of 0.29% and Acquired Fund Fees and Expenses of 0.99% for a gross expense ratio of 1.28%. FIVY has a Management Fee of 0.29% and Acquired Fund Fees and Expenses of 0.59% for a gross expense ratio of 0.88%. “Acquired Fund Fees and Expenses” are indirect fees and expenses that the Fund incurs from investing in the shares of other investment companies, namely other YieldMax™ ETFs. ULTY has a gross expense ratio after the fee waiver of 1.30%. The Advisor has agreed to a fee waiver of 0.10% through at least February 28, 2026.


2

 The Distribution Rate shown is as of close on April 15, 2025. The Distribution Rate is the annual distribution rate an investor would receive if the most recent distribution, which includes option income, remained the same going forward. The Distribution Rate is calculated by annualizing an ETF’s Distribution per Share and dividing such annualized amount by the ETF’s most recent NAV. The Distribution Rate represents a single distribution from the ETF and does not represent its total return. Distributions may also include a combination of ordinary dividends, capital gain, and return of investor capital, which may decrease an ETF’s NAV and trading price over time. As a result, an investor may suffer significant losses to their investment. These Distribution Rates may be caused by unusually favorable market conditions and may not be sustainable. Such conditions may not continue to exist and there should be no expectation that this performance may be repeated in the future.


3
 The 30-Day SEC Yield represents net investment income, which excludes option income, earned by such ETF over the 30-Day period ended March 31, 2025, expressed as an annual percentage rate based on such ETF’s share price at the end of the 30-Day period.


4

 Each ETF’s strategy (except those of the Short ETFs) will cap potential gains if its reference asset’s shares increase in value, yet subjects an investor to all potential losses if the reference asset’s shares decrease in value. Such potential losses may not be offset by income received by the ETF. Each Short ETF’s strategy will cap potential gains if its reference asset decreases in value, yet subjects an investor to all potential losses if the reference asset increases in value. Such potential losses may not be offset by income received by the ETF.


5  

ROC refers to Return of Capital. The ROC percentage is the portion of the distribution that represents an investor’s original investment.

Each Fund has a limited operating history and while each Fund’s objective is to provide current income, there is no guarantee the Fund will make a distribution. Distributions are likely to vary greatly in amount.


Standardized Performance

For YMAX, click here. For YMAG, click here. For TSLY, click here. For OARK, click here. For APLY, click here. For NVDY, click here. For AMZY, click here. For FBY, click here. For GOOY, click here. For NFLY, click here. For CONY, click here. For MSFO, click here. For DISO, click here. For XOMO, click here. For JPMO, click here. For AMDY, click here. For PYPY, click here. For XYZY, click here. For MRNY, click here. For AIYY, click here. For MSTY, click here. For ULTY, click here. For YBIT, click here. For CRSH, click here. For GDXY, click here. For SNOY, click here. For ABNY, click here. For FIAT, click here. For DIPS, click here. For BABO, click here. For YQQQ, click here. For TSMY, click here. For SMCY, click here. For PLTY, click here. For BIGY, click here. For SOXY, click here. For MARO, click here. For FEAT, click here. For FIVY, click here. For LFGY, click here. For GPTY, click here. For CVNY, click here. For SDTY, click here. For QDTY, click here. For WNTR, click here. For CHPY, click here.


Important Information

This material must be preceded or accompanied by the prospectus. For all prospectuses, click here.

Tidal Financial Group is the adviser for all YieldMax™ ETFs.

THE FUND, TRUST, AND ADVISER ARE NOT AFFILIATED WITH ANY UNDERLYING REFERENCE ASSET.


Risk Disclosures (applicable to all YieldMax ETFs referenced above, except the Short ETFs)

YMAX, YMAG, FEAT and FIVY generally invest in other YieldMax™ ETFs. As such, these two Funds are subject to the risks listed in this section, which apply to all the YieldMax™ ETFs they may hold from time to time.

Investing involves risk. Principal loss is possible.

Referenced Index Risk. The Fund invests in options contracts that are based on the value of the Index (or the Index ETFs). This subjects the Fund to certain of the same risks as if it owned shares of companies that comprised the Index or an ETF that tracks the Index, even though it does not.

Indirect Investment Risk. The Index is not affiliated with the Trust, the Fund, the Adviser, or their respective affiliates and is not involved with this offering in any way. Investors in the Fund will not have the right to receive dividends or other distributions or any other rights with respect to the companies that comprise the Index but will be subject to declines in the performance of the Index.

Russell 2000 Index Risks. The Index, which consists of small-cap U.S. companies, is particularly susceptible to economic changes, as these firms often have less financial resilience than larger companies. Market volatility can disproportionately affect these smaller businesses, leading to significant price swings. Additionally, these companies are often more exposed to specific industry risks and have less diverse revenue streams. They can also be more vulnerable to changes in domestic regulatory or policy environments.

Call Writing Strategy Risk. The path dependency (i.e., the continued use) of the Fund’s call writing strategy will impact the extent that the Fund participates in the positive price returns of the underlying reference asset and, in turn, the Fund’s returns, both during the term of the sold call options and over longer periods.

Counterparty Risk. The Fund is subject to counterparty risk by virtue of its investments in options contracts. Transactions in some types of derivatives, including options, are required to be centrally cleared (“cleared derivatives”). In a transaction involving cleared derivatives, the Fund’s counterparty is a clearing house rather than a bank or broker. Since the Fund is not a member of clearing houses and only members of a clearing house (“clearing members”) can participate directly in the clearing house, the Fund will hold cleared derivatives through accounts at clearing members.

Derivatives Risk. Derivatives are financial instruments that derive value from the underlying reference asset or assets, such as stocks, bonds, or funds (including ETFs), interest rates or indexes. The Fund’s investments in derivatives may pose risks in addition to, and greater than, those associated with directly investing in securities or other ordinary investments, including risk related to the market, imperfect correlation with underlying investments or the Fund’s other portfolio holdings, higher price volatility, lack of availability, counterparty risk, liquidity, valuation and legal restrictions. 

Options Contracts. The use of options contracts involves investment strategies and risks different from those associated with ordinary portfolio securities transactions. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in the value of the underlying instrument, including the anticipated volatility, which are affected by fiscal and monetary policies and by national and international political, changes in the actual or implied volatility or the reference asset, the time remaining until the expiration of the option contract and economic events.

Distribution Risk. As part of the Fund’s investment objective, the Fund seeks to provide current income. There is no assurance that the Fund will make a distribution in any given period. If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

High Portfolio Turnover Risk. The Fund may actively and frequently trade all or a significant portion of the Fund’s holdings. A high portfolio turnover rate increases transaction costs, which may increase the Fund’s expenses.

Liquidity Risk. Some securities held by the Fund, including options contracts, may be difficult to sell or be illiquid, particularly during times of market turmoil.

Non-Diversification Risk. Because the Fund is “non-diversified,” it may invest a greater percentage of its assets in the securities of a single issuer or a smaller number of issuers than if it was a diversified fund.

New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors do not have a track record or history on which to base their investment decisions.

Price Participation Risk. The Fund employs an investment strategy that includes the sale of call option contracts, which limits the degree to which the Fund will participate in increases in value experienced by the underlying reference asset over the Call Period.

Single Issuer Risk. Issuer-specific attributes may cause an investment in the Fund to be more volatile than a traditional pooled investment which diversifies risk or the market generally. The value of the Fund, which focuses on an individual security (ARKK, TSLA, AAPL, NVDA, AMZN, META, GOOGL, NFLX, COIN, MSFT, DIS, XOM, JPM, AMD, PYPL, SQ, MRNA, AI, MSTR, Bitcoin ETP, GDX®, SNOW, ABNB, BABA, TSM, SMCI, PLTR, MARA, CVNA), may be more volatile than a traditional pooled investment or the market as a whole and may perform differently from the value of a traditional pooled investment or the market as a whole.

Inflation Risk. Inflation risk is the risk that the value of assets or income from investments will be less in the future as inflation decreases the value of money. As inflation increases, the present value of the Fund’s assets and distributions, if any, may decline.

Indirect Investment Risk. The Index is not affiliated with the Trust, the Fund, the Adviser, or their respective affiliates and is not involved with this offering in any way.


Risk Disclosures (applicable only to GPTY)

Artificial Intelligence Risk. Issuers engaged in artificial intelligence typically have high research and capital expenditures and, as a result, their profitability can vary widely, if they are profitable at all. The space in which they are engaged is highly competitive and issuers’ products and services may become obsolete very quickly. These companies are heavily dependent on intellectual property rights and may be adversely affected by loss or impairment of those rights. The issuers are also subject to legal, regulatory, and political changes that may have a large impact on their profitability. A failure in an issuer’s product or even questions about the safety of the product could be devastating to the issuer, especially if it is the marquee product of the issuer. It can be difficult to accurately capture what qualifies as an artificial intelligence company.

Technology Sector Risk. The Fund will invest substantially in companies in the information technology sector, and therefore the performance of the Fund could be negatively impacted by events affecting this sector. Market or economic factors impacting technology companies and companies that rely heavily on technological advances could have a significant effect on the value of the Fund’s investments. The value of stocks of information technology companies and companies that rely heavily on technology is particularly vulnerable to rapid changes in technology product cycles, rapid product obsolescence, government regulation and competition, both domestically and internationally, including competition from foreign competitors with lower production costs. Stocks of information technology companies and companies that rely heavily on technology, especially those of smaller, less-seasoned companies, tend to be more volatile than the overall market. Information technology companies are heavily dependent on patent and intellectual property rights, the loss or impairment of which may adversely affect profitability.


Risk Disclosure (applicable only to MARO)

Digital Assets Risk: The Fund does not invest directly in Bitcoin or any other digital assets. The Fund does not invest directly in derivatives that track the performance of Bitcoin or any other digital assets. The Fund does not invest in or seek direct exposure to the current “spot” or cash price of Bitcoin. Investors seeking direct exposure to the price of Bitcoin should consider an investment other than the Fund. Digital assets like Bitcoin, designed as mediums of exchange, are still an emerging asset class. They operate independently of any central authority or government backing and are subject to regulatory changes and extreme price volatility.


Risk Disclosures (applicable only to BABO and TSMY)

Currency Risk: Indirect exposure to foreign currencies subjects the Fund to the risk that currencies will decline in value relative to the U.S. dollar. Currency rates in foreign countries may fluctuate significantly over short periods of time for a number of reasons, including changes in interest rates and the imposition of currency controls or other political developments in the U.S. or abroad.

Depositary Receipts Risk: The securities underlying BABO and TSMY are American Depositary Receipts (“ADRs”). Investment in ADRs may be less liquid than the underlying shares in their primary trading market.

Foreign Market and Trading Risk: The trading markets for many foreign securities are not as active as U.S. markets and may have less governmental regulation and oversight.

Foreign Securities Risk: Investments in securities of non-U.S. issuers involve certain risks that may not be present with investments in securities of U.S. issuers, such as risk of loss due to foreign currency fluctuations or to political or economic instability, as well as varying regulatory requirements applicable to investments in non-U.S. issuers. There may be less information publicly available about a non-U.S. issuer than a U.S. issuer. Non-U.S. issuers may also be subject to different regulatory, accounting, auditing, financial reporting, and investor protection standards than U.S. issuers.


Risk Disclosures (applicable only to GDXY)

Risk of Investing in Foreign Securities. The Fund is exposed indirectly to the securities of foreign issuers selected by GDX®’s investment adviser, which subjects the Fund to the risks associated with such companies. Investments in the securities of foreign issuers involve risks beyond those associated with investments in U.S. securities.

Risk of Investing in Gold and Silver Mining Companies. The Fund is exposed indirectly to gold and silver mining companies selected by GDX®’s investment adviser, which subjects the Fund to the risks associated with such companies.

The Fund invests in options contracts based on the value of the VanEck Gold Miners ETF (GDX®), which subjects the Fund to some of the same risks as if it owned GDX®, as well as the risks associated with Canadian, Australian and Emerging Market Issuers, and Small-and Medium-Capitalization companies.


Risk Disclosures (applicable only to YBIT)

YBIT does not invest directly in Bitcoin or any other digital assets. YBIT does not invest directly in derivatives that track the performance of Bitcoin or any other digital assets. YBIT does not invest in or seek direct exposure to the current “spot” or cash price of Bitcoin. Investors seeking direct exposure to the price of Bitcoin should consider an investment other than YBIT.

Bitcoin Investment Risk: The Fund’s indirect investment in Bitcoin, through holdings in one or more Underlying ETPs, exposes it to the unique risks of this emerging innovation. Bitcoin’s price is highly volatile, and its market is influenced by the changing Bitcoin network, fluctuating acceptance levels, and unpredictable usage trends.

Digital Assets Risk: Digital assets like Bitcoin, designed as mediums of exchange, are still an emerging asset class. They operate independently of any central authority or government backing and are subject to regulatory changes and extreme price volatility. Potentially No 1940 Act Protections. As of the date of this Prospectus, there is only a single eligible Underlying ETP, and it is an investment company subject to the 1940 Act.

Bitcoin
ETP Risk: The Fund invests in options contracts that are based on the value of the Bitcoin ETP. This subjects the Fund to certain of the same risks as if it owned shares of the Bitcoin ETP, even though it does not. Bitcoin ETPs are subject, but not limited, to significant risk and heightened volatility. An investor in a Bitcoin ETP may lose their entire investment. Bitcoin ETPs are not suitable for all investors. In addition, not all Bitcoin ETPs are registered under the Investment Company Act of 1940. Those Bitcoin ETPs that are not registered under such statute are therefore not subject to the same regulations as exchange traded products that are so registered.


Risk Disclosures (applicable only to the Short ETFs)

Investing involves risk. Principal loss is possible.

Price Appreciation Risk. As part of the Fund’s synthetic covered put strategy, the Fund purchases and sells call and put option contracts that are based on the value of the underlying reference asset. This strategy subjects the Fund to certain of the same risks as if it shorted the underlying reference asset, even though it does not. By virtue of the Fund’s indirect inverse exposure to changes in the value of the underlying reference asset, the Fund is subject to the risk that the value of the underlying reference asset increases. If the value of the underlying reference asset increases, the Fund will likely lose value and, as a result, the Fund may suffer significant losses.

Put Writing Strategy Risk. The path dependency (i.e., the continued use) of the Fund’s put writing (selling) strategy will impact the extent that the Fund participates in decreases in the value of the underlying reference asset and, in turn, the Fund’s returns, both during the term of the sold put options and over longer periods.

Purchased OTM Call Options Risk. The Fund’s strategy is subject to potential losses if the underlying reference asset increases in value, which may not be offset by the purchase of out-of-the-money (OTM) call options. The Fund purchases OTM calls to seek to manage (cap) the Fund’s potential losses from the Fund’s short exposure to the underlying reference asset if it appreciates significantly in value. However, the OTM call options will cap the Fund’s losses only to the extent that the value of the underlying reference asset increases to a level that is at or above the strike level of the purchased OTM call options. Any increase in the value of the underlying reference asset to a level that is below the strike level of the purchased OTM call options will result in a corresponding loss for the Fund. For example, if the OTM call options have a strike level that is approximately 100% above the then-current value of the underlying reference asset at the time of the call option purchase, and the value of the underlying reference asset increases by at least 100% during the term of the purchased OTM call options, the Fund will lose all its value. Since the Fund bears the costs of purchasing the OTM calls, such costs will decrease the Fund’s value and/or any income otherwise generated by the Fund’s investment strategy.

Counterparty Risk. The Fund is subject to counterparty risk by virtue of its investments in options contracts. Transactions in some types of derivatives, including options, are required to be centrally cleared (“cleared derivatives”). In a transaction involving cleared derivatives, the Fund’s counterparty is a clearing house rather than a bank or broker. Since the Fund is not a member of clearing houses and only members of a clearing house (“clearing members”) can participate directly in the clearing house, the Fund will hold cleared derivatives through accounts at clearing members.

Derivatives Risk. Derivatives are financial instruments that derive value from the underlying reference asset or assets, such as stocks, bonds, or funds (including ETFs), interest rates or indexes. The Fund’s investments in derivatives may pose risks in addition to, and greater than, those associated with directly investing in securities or other ordinary investments, including risk related to the market, imperfect correlation with underlying investments or the Fund’s other portfolio holdings, higher price volatility, lack of availability, counterparty risk, liquidity, valuation and legal restrictions. 

Options Contracts. The use of options contracts involves investment strategies and risks different from those associated with ordinary portfolio securities transactions. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in the value of the underlying reference asset, including the anticipated volatility, which are affected by fiscal and monetary policies and by national and international political, changes in the actual or implied volatility or the reference asset, the time remaining until the expiration of the option contract and economic events.

Distribution Risk. As part of the Fund’s investment objective, the Fund seeks to provide current income. There is no assurance that the Fund will make a distribution in any given period. If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

High Portfolio Turnover Risk. The Fund may actively and frequently trade all or a significant portion of the Fund’s holdings.

Liquidity Risk. Some securities held by the Fund, including options contracts, may be difficult to sell or be illiquid, particularly during times of market turmoil.

Non-Diversification Risk. Because the Fund is “non-diversified,” it may invest a greater percentage of its assets in the securities of a single issuer or a smaller number of issuers than if it was a diversified fund.

New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors do not have a track record or history on which to base their investment decisions.

Price Participation Risk. The Fund employs an investment strategy that includes the sale of put option contracts, which limits the degree to which the Fund will participate in decreases in value experienced by the underlying reference asset over the Put Period.

Single Issuer Risk. Issuer-specific attributes may cause an investment in the Fund to be more volatile than a traditional pooled investment which diversifies risk or the market generally. The value of the Fund, for any Fund that focuses on an individual security (e.g., TSLA, COIN, NVDA, MSTR), may be more volatile than a traditional pooled investment or the market as a whole and may perform differently from the value of a traditional pooled investment or the market as a whole. 

Inflation Risk. Inflation risk is the risk that the value of assets or income from investments will be less in the future as inflation decreases the value of money. As inflation increases, the present value of the Fund’s assets and distributions, if any, may decline.


Risk Disclosures (applicable only to CHPY)

Semiconductor Industry Risk. Semiconductor companies may face intense competition, both domestically and internationally, and such competition may have an adverse effect on their profit margins. Semiconductor companies may have limited product lines, markets, financial resources or personnel. Semiconductor companies’ supply chain and operations are dependent on the availability of materials that meet exacting standards and the use of third parties to provide components and services.

The products of semiconductor companies may face obsolescence due to rapid technological developments and frequent new product introduction, unpredictable changes in growth rates and competition for the services of qualified personnel. Capital equipment expenditures could be substantial, and equipment generally suffers from rapid obsolescence. Companies in the semiconductor industry are heavily dependent on patent and intellectual property rights. The loss or impairment of these rights would adversely affect the profitability of these companies.


Risk Disclosures (applicable only to YQQQ)

Index Overview. The Nasdaq 100 Index is a benchmark index that includes 100 of the largest non-financial companies listed on the Nasdaq Stock Market, based on market capitalization.

Index Level Appreciation Risk. As part of the Fund’s synthetic covered put strategy, the Fund purchases and sells call and put option contracts that are based on the Index level. This strategy subjects the Fund to certain of the same risks as if it shorted the Index, even though it does not. By virtue of the Fund’s indirect inverse exposure to changes in the Index level, the Fund is subject to the risk that the Index level increases. If the Index level increases, the Fund will likely lose value and, as a result, the Fund may suffer significant losses. The Fund may also be subject to the following risks: innovation and technological advancement; strong market presence of Index constituent companies; adaptability to global market trends; and resilience and recovery potential.

Index Level Participation Risk. The Fund employs an investment strategy that includes the sale of put option contracts, which limits the degree to which the Fund will benefit from decreases in the Index level experienced over the Put Period. This means that if the Index level experiences a decrease in value below the strike level of the sold put options during a Put Period, the Fund will likely not experience that increase to the same extent and any Fund gains may significantly differ from the level of the Index losses over the Put Period. Additionally, because the Fund is limited in the degree to which it will participate in decreases in value experienced by the Index level over each Put Period, but has significant negative exposure to any increases in value experienced by the Index level over the Put Period, the NAV of the Fund may decrease over any given period. The Fund’s NAV is dependent on the value of each options portfolio, which is based principally upon the inverse of the performance of the Index level. The Fund’s ability to benefit from the Index level decreases will depend on prevailing market conditions, especially market volatility, at the time the Fund enters into the sold put option contracts and will vary from Put Period to Put Period. The value of the options contracts is affected by changes in the value and dividend rates of component companies that comprise the Index, changes in interest rates, changes in the actual or perceived volatility of the Index and the remaining time to the options’ expiration, as well as trading conditions in the options market. As the Index level changes and time moves towards the expiration of each Put Period, the value of the options contracts, and therefore the Fund’s NAV, will change. However, it is not expected for the Fund’s NAV to directly inversely correlate on a day-to-day basis with the returns of the Index level. The amount of time remaining until the options contract’s expiration date affects the impact that the value of the options contracts has on the Fund’s NAV, which may not be in full effect until the expiration date of the Fund’s options contracts. Therefore, while changes in the Index level will result in changes to the Fund’s NAV, the Fund generally anticipates that the rate of change in the Fund’s NAV will be different than the inverse of the changes experienced by the Index level.

YieldMax™ ETFs are distributed by Foreside Fund Services, LLC. Foreside is not affiliated with Tidal Financial Group, or YieldMax™ ETFs.

© 2025 YieldMax™ ETFs



Contact Gavin Filmore at [email protected] for more information.

SRM Entertainment’s Provides Update on Trade Related Market Conditions

Winter Park, FL, April 16, 2025 (GLOBE NEWSWIRE) — SRM Entertainment, Inc. (Nasdaq: SRM) SRM Entertainment maintains a favorable business model for current trade conditions. SRM manufactures products in China and more importantly SRM “passes title” of our products to our largest customers in China. Shipping, tariffs and other duty related expenses are the responsibility of our customers. This business model provides SRM with the ability to mitigate changing trade conditions. In addition, SRM carries inventory of our proprietary products in the United States of approximately $800,000 which is sold through retailers and Amazon. This domestic asset provides the Company with a readily available supply of key products such as lovable plush, back pack clips, drinkware and SRM’s Sip with Me cups including the officially licensed Smurfs collectible line insulating at least a portion of our business from potential supply chain disruptions and tariff-related cost increases.

SRM services a diversified customer base across multiple entertainment sectors, including theme parks, retail, e-commerce, and media. This should help SRM manage any trade related disruptions. The Company’s strategic focus on building a high quality and geographically diverse supply chain underscores its commitment to long-term stability and profitability in the face of shifting global economic trade policies.

SRM continues to drive positive results as we continue to receive product re-orders from our largest theme park customers, demonstrating the enduring popularity and demand for our high-quality themed merchandise. In addition, SRM international theme park customers are not impacted by tariffs on imports into the United States.

SRM is utilizing proactive strategies to mitigate the impact of trade related tariffs, ensuring continued strong operations and high-quality product delivery to its valued customers. SRM is continuing efforts to expand manufacturing capacity into new countries in addition to seeking domestic USA based cost effective manufacturing solutions to maintain product quality, competitive pricing and supply chain efficiencies.

“SRM is confident in our ability to maintain and develop strong customer relationships in this rapidly evolving trade and tariff landscape.” said Rich Miller, CEO of SRM Entertainment. “Our domestic inventory position for our retailers and Amazon products provide us with needed flexibility, plus the Smurfs movie starring pop superstar Rihanna is being released this July and we already have officially licensed Smurfs collectible Sip with Me kids cups in the USA ready to go.”

About SRM Entertainment, Inc.

SRM Entertainment designs, develops, and manufactures custom merchandise which includes toys and souvenirs for the world’s largest theme parks and other entertainment venues. Many of SRM’s creative products are based on award winning multi-billion-dollar entertainment franchises that are featured in popular movies and books. SRM products are distributed worldwide at Walt Disney Parks and Resorts, Universal Parks and Destinations, United Parks and Resorts – SeaWorld, Six Flags and other attractions. SRM’s products are offered alongside popular rides and attractions in theme parks, zoos, aquariums, and other entertainment venues. SRM’s design team developed specialty dolls, plush and toys for one of New York City’s landmarks that features a popular holiday show. SRM’s design team is credited with creating popular products which have been successfully sold at specialty theme park events. SRM’s exclusive-patented Sip With Me cups feature fun, kid friendly Zoo, Sea and animal themed characters as well as licensed characters from Smurfs, ICEE and Zoonicorn.

Caution Regarding Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. These statements are subject to uncertainties and risks including, but not limited to, the risk factors discussed in the “Risk Factors” section of the Company’s filings with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. The current global tariff environment is uncertain. For products manufactured outside the U.S., tariffs increase the cost of our products. Most of our products are produced in China, and tariffs may impact our sales and reduce our profitability as a result. Tariffs may also impact consumer spending if products become more expensive, or consumers have less discretionary income or consumer spending power. The current tariff environment, particularly the imposition or threat of tariffs on products manufactured in China for import into the U.S. as well the potential for retaliatory and reciprocal tariffs in other countries in which we do business, may negatively impact our business, sales and profitability. While our contracts currently require our customers to cover tariffs and other fees, further increases in tariffs may increase the costs of our products. We cannot assure you that we will be able to successfully implement actions to lessen the impact of tariffs imposed on our products, including any changes to our supply chain, logistics capabilities, sales policies or pricing of our products.

Media and Investor Relations


[email protected]


(407)-230-8100
website: SRMentertainment.com



Kenvue Announces 5-Year Collaboration with Microsoft to Transform Digital Operations

Kenvue Announces 5-Year Collaboration with Microsoft to Transform Digital Operations

SUMMIT, N.J.–(BUSINESS WIRE)–
Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced a five-year collaboration with Microsoft which aims to establish a strong foundation for transforming digital operations through advanced Artificial Intelligence (AI) technologies. These technologies include machine-enabled collaboration, predictive analytics, smart agents, digital twins, and generative AI. By advancing predictive and AI-assisted capabilities, Kenvue aims to set new standards for innovation across commercial, operations, and technology practices ultimately delivering enhanced consumer experiences, increased productivity, and sustained growth.

Over the next five years, Kenvue will scale its use of Microsoft Azure to capitalize on its wide range of services including data analytics and AI. The integration of Azure services will enhance predictive capabilities and human-machine collaboration. In addition, Kenvue aims to drive innovation, refine go-to-market strategies, enhance customer experiences, and optimize commercial operations to put the power of everyday care into the hands of consumers around the world.

Harnessing real-time algorithmic capabilities and AI / generative AI-powered solutions, Kenvue’s move to Azure will allow Kenvue to:

  • Accelerate product development, enhance formulations, and optimize clinical research data helping ensure consumers have access to the most advanced health solutions;
  • Advance data-driven go-to-market strategies, personalizing consumer experiences, tailoring product recommendations, and enhancing omnichannel engagement;
  • Deepen customer collaboration and enhance retail excellence and visibility through algorithmic selling supported by advanced forecasting and intelligent automation to improve inventory management and reduce waste; and
  • Further optimize business processes, drive efficiencies in hopes of unlocking new growth opportunities, and adopt new and emerging platforms.

“This exciting collaboration will help Kenvue on its journey to becoming the undisputed leader in consumer health,” says Bernardo Tavares, Chief Technology & Data Officer at Kenvue. “Harnessing the power of data and AI at Kenvue equips our teams to accelerate product development, optimize decisions, and create seamless, personalized consumer experiences, all while keeping consumers’ privacy and trust at the forefront. By transforming our digital operations, we expect to create predictive business solutions and win more consumers every day.”

Shelley Bransten, Corporate Vice President, Global Industry Solutions at Microsoft added, “This collaboration showcases the transformative potential of AI, and together, we are dedicated to building a future where predictive capabilities and human-machine collaboration serve as powerful, trusted tools to help improve consumer health and unlock breakthrough innovations.”

Kenvue is already piloting the use of systems and tools that integrate Microsoft Azure AI, Microsoft 365 Copilot, and Copilot Studio, in connection with supply chain and operations, content creation, as well as in various Kenvuer productivity enhancement use cases. By advancing predictive and AI –assisted capabilities, Kenvue, along with the Kenvue ecosystem of digital partners, strive to establish a new benchmark for innovation in consumer health.

About Kenvue

Kenvue Inc. is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding a five-year collaboration with Microsoft to transform Kenvue’s digital operations. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue and its affiliates.

A list and descriptions of risks, uncertainties and other factors can be found in Kenvue’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.

Melissa Witt, [email protected]

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Technology Professional Services Software Health Data Analytics Cosmetics General Health Retail Artificial Intelligence

MEDIA:

Logo
Logo

Movado Group, Inc. Announces Fourth Quarter and Fiscal Year 2025 Results

Movado Group, Inc. Announces Fourth Quarter and Fiscal Year 2025 Results

~ Fiscal 2025 Net Sales of $653.4 million ~

~ Fiscal 2025 Operating Income of $20.0 million and Adjusted Operating Income of $27.1 million ~

~ Fiscal 2025 EPS of $0.81 and Fiscal 2025 Adjusted EPS of $1.12 ~

~ Fourth Quarter Net Sales of $181.5 million ~

~ Fourth Quarter EPS of $0.36 and Fourth Quarter Adjusted EPS of $0.51 ~

~ Board Declared Quarterly Dividend of $0.35 Per Share ~

PARAMUS, N.J.–(BUSINESS WIRE)–
Movado Group, Inc. (NYSE: MOV) today announced fourth quarter and fiscal year 2025 results for the periods ended January 31, 2025. As previously announced, on April 11, 2025, the Company filed a Current Report on Form 8-K in which it presented restated prior-period financial results for each of the three fiscal years ended January 31, 2024, and the interim periods within fiscal years 2025 and 2024. As a result, the historical periods presented in this press release incorporate the restated financial results.

Fiscal Year 2025 Highlights (See attached table for GAAP and Non-GAAP measures)

  • Net sales of $653.4 million vs. $664.4 million in fiscal 2024;
  • Operating income of $20.0 million compared to $48.5 million in the prior year period;
  • Adjusted operating income of $27.1 million in fiscal 2025;
  • Diluted earnings per share of $0.81 compared to $1.83 in the prior year period;
  • Adjusted diluted earnings per share of $1.12 in fiscal 2025; and
  • Ended the year with cash of $208.5 million and no debt.

Efraim Grinberg, Chairman and Chief Executive Officer, stated: “Despite a challenging macroeconomic backdrop, we delivered net sales growth in the fourth quarter and also expanded gross profit margin while increasing marketing spend in support of future growth. As we communicated when reporting third quarter results in December, we increased our focus on reducing go-forward operating expenses. As of our fiscal year end, we had already implemented actions that are expected to deliver $10 million in annualized savings while increasing efficiency across our enterprise in order to generate higher productivity and profitability. Additionally, we will bring our marketing spend to be more in line with sales in fiscal 2026, with planned spend being reduced by a range of $15 million to $20 million relative to fiscal 2025.”

“Given the ongoing uncertainty within the global retail environment, tariffs, and economic unrest that may ensue, we will continue to focus on the areas that we can control. We have always prided ourselves on strong execution, delivering innovation for our customers and brands, and driving demand through effective marketing messaging across our brand portfolio.”

Mr. Grinberg concluded, “Introducing innovation across our watch and jewelry brands globally, executing with discipline, and leveraging our strong balance sheet with $208.5 million in cash and no debt will continue to serve us well as we navigate the current uncertain global economic environment. We are pleased that last Friday we announced that our board had declared a quarterly dividend of $0.35 per share, and we remain committed to prioritizing returning value to shareholders through ongoing quarterly cash dividends and our share repurchase program.”

Fiscal Fourth Quarter Highlights (See attached table for GAAP and Non-GAAP measures)

  • Net sales of $181.5 million versus $175.8 million in the fourth quarter of fiscal 2024;
  • Gross margin of 54.2% as compared to 53.5% in the prior year period;
  • Operating income of $9.2 million as compared to $10.8 million in the prior year period;
  • Adjusted operating income of $13.5 million in the fourth quarter of fiscal 2025;
  • Diluted earnings per share of $0.36 as compared to $0.43 in the prior year period; and
  • Adjusted diluted earnings per share was $0.51 in the fourth quarter of fiscal 2025.

Non-GAAP Items (See attached table for GAAP and Non-GAAP measures)

Fiscal 2025 results of operations included the following items:

  • a fourth quarter pre-tax charge of $1.8 million, or $1.5 million after tax, representing $0.07 per diluted share, associated with the establishment of a provision associated with a corporate cost-savings initiative. For the full fiscal year, the pre-tax charge was $4.6 million, or $3.7 million after tax, representing $0.16 per diluted share.
  • a fourth quarter and full year pre-tax charge of $2.5 million, or $1.9 million after tax, representing $0.08 per diluted share, associated with professional fees related to the investigation of conduct by certain employees of the Company’s Dubai branch.
  • a full year after tax charge of $1.5 million, representing $0.07 per diluted share, associated with the tax impact of repatriation of foreign earnings, primarily related to foreign currency gains.

In this press release, references to “adjusted” results exclude the impact of the above charges. Please refer to the attached GAAP and Non-GAAP measures table for a detailed reconciliation of the Company’s reported results to its adjusted, non-GAAP results.

Fourth Quarter Fiscal 2025 Results (See attached table for GAAP and Non-GAAP measures)

  • Net sales increased 3.3% to $181.5 million, or increased 5.0% on a constant dollar basis, compared to $175.8 million in the fourth quarter of fiscal 2024. The increase in net sales reflected growth in international wholesale channels and online retail, partially offset by declines in U.S. wholesale customers’ brick and mortar stores and Movado Company Stores, as well as the negative impact of fluctuations in foreign exchange rates. U.S. net sales decreased 2.9% as compared to the fourth quarter of last year. International net sales increased 8.8% (an increase of 12.2% on a constant dollar basis) as compared to the fourth quarter of last year.
  • Gross profit was $98.3 million, or 54.2% of net sales, compared to $94.1 million, or 53.5% of net sales in the fourth quarter of fiscal 2024. The increase in gross margin percentage was primarily the result of favorable changes in channel and product mix and the increased leverage of lower fixed costs over higher sales, partially offset by the unfavorable impact of foreign currency exchange rates.
  • Operating expenses were $89.1 million in the fourth quarter of fiscal 2025 compared to $83.3 million in the fourth quarter of fiscal 2024. Adjusted operating expenses were $84.8 million for the fourth quarter of fiscal 2025. The change in operating expenses was primarily due to higher marketing expenses and the charges described above under “Non-GAAP Items,” partially offset by lower payroll and related expenses.
  • Operating income was $9.2 million compared to $10.8 million in the fourth quarter of fiscal 2024. Adjusted operating income was $13.5 million for the fourth quarter of fiscal 2025.
  • The Company recorded a tax provision of $2.2 million, as compared to a tax provision of $2.3 million in the fourth quarter of fiscal 2024. Based on adjusted pre-tax income, the adjusted tax provision was $3.1 million, or an adjusted tax rate of 20.6%, as compared to a tax rate of 18.9%, in the fourth quarter of fiscal 2024.
  • Net income for the fourth quarter of fiscal 2025 was $8.1 million, or $0.36 per diluted share, compared to net income of $9.8 million, or $0.43 per diluted share, in the fourth quarter of fiscal 2024. Adjusted net income for the fiscal 2025 period was $11.5 million, or $0.51 per diluted share.

Full Year Fiscal 2025 Results (See attached table for GAAP and Non-GAAP measures)

  • Net sales decreased 1.7% to $653.4 million, or decreased 1.5% on a constant dollar basis, compared to $664.4 million in fiscal 2024. The decrease in net sales reflected declines in U.S. wholesale customers’ brick and mortar stores and Movado Company Stores, as well as the negative impact of fluctuations in foreign exchange rates, partially offset by growth in online retail in the U.S. and in international wholesale channels. Net sales decreased 4.0% in the U.S. as compared to fiscal 2024. International net sales increased 0.2% (an increase of 0.6% on a constant dollar basis) as compared to fiscal 2024.
  • Gross profit was $353.1 million, or 54.0% of net sales, compared to gross profit of $364.2 million, or 54.8% of net sales in fiscal 2024. The decrease in gross margin percentage was primarily the result of unfavorable changes in channel and product mix, the decreased leverage of higher fixed costs over lower sales and the unfavorable impact of foreign currency exchange rates, partially offset by reduced shipping costs.
  • Operating expenses were $333.1 million in fiscal 2025 compared to $315.7 million in fiscal 2024. For fiscal 2025, adjusted operating expenses were $326.1 million. This increase was primarily due to higher marketing expense and the charges described above under “Non-GAAP Items,” partially offset by lower performance-based compensation.
  • Operating income was $20.0 million in fiscal 2025 as compared to operating income of $48.5 million in fiscal 2024. Adjusted operating income for fiscal 2025 was $27.1 million.
  • The Company recorded a tax provision of $7.4 million in fiscal 2025 compared to a tax provision of $11.8 million in fiscal 2024. Based on adjusted pre-tax income, the adjusted tax provision was $7.4 million, or an adjusted tax rate of 22.0%, as compared to a tax rate of 21.9% in fiscal 2024.
  • Net income was $18.4 million, or $0.81 per diluted share, for fiscal 2025, compared to net income of $41.3 million, or $1.83 per diluted share, for fiscal 2024. Adjusted net income in fiscal 2025 was $25.4 million or $1.12 per diluted share.

Fiscal 2026 Outlook

Given the current economic uncertainty and the unpredictable impact of recent tariff developments on the Company’s business, the Company has elected not to provide a fiscal 2026 outlook at this time. However, the Company is planning to take actions to partially mitigate the impact of the recent tariff changes, including select price increases at the wholesale and retail levels.

Quarterly Dividend and Share Repurchase Program

The Company also announced on April 11, 2025, that the Board of Directors approved the payment on May 6, 2025, of a cash dividend in the amount of $0.35 for each share of the Company’s outstanding common stock and class A common stock held by shareholders of record as of the close of business on April 22, 2025.

During fiscal year 2025, the Company repurchased approximately 120,000 shares under its November 23, 2021, share repurchase program which expired on November 23, 2024. As of year-end, the Company had $50.0 million remaining available under its December 5, 2024 share repurchase program.

Conference Call

The Company’s management will host a conference call and audio webcast to discuss its results today, April 16, 2025, at 9:00 a.m. Eastern Time. The conference call may be accessed by dialing (877) 407-0784. Additionally, a live webcast of the call can be accessed at www.movadogroup.com.The webcast will be archived on the Company’s website approximately one hour after the conclusion of the call. Additionally, a telephonic replay of the call will be available from 1:00 p.m. ET on April 16, 2025, until 11:59 p.m. ET on April 30, 2025, and can be accessed by dialing (844) 512-2921 and entering replay pin number 13752902.

Movado Group, Inc. designs, sources, and globally distributes and sells MOVADO®, MVMT®, OLIVIA BURTON®, EBEL®, CONCORD®, CALVIN KLEIN®, COACH®, TOMMY HILFIGER®, HUGO BOSS®, and LACOSTE® watches and, to a lesser extent, jewelry and other accessories, and operates Movado Company Stores in the United States and Canada.

In this release, the Company presents certain financial measures that are not calculated according to generally accepted accounting principles in the United States (“GAAP”). Specifically, the Company is presenting adjusted operating expenses, diluted earnings per share, adjusted diluted earnings per share, adjusted operating income, adjusted pre-tax income, adjusted tax provision and adjusted net income, which are operating expenses, operating income, pre-tax income, tax provision and net income, respectively, under GAAP, adjusted to eliminate the establishment of a provision associated with a cost-savings initiative, professional fees related to the investigation referred to above and the impact of the repatriation of foreign earnings. The Company believes these adjusted measures are useful because they give investors information about the Company’s financial performance without the effect of certain items that the Company believes are not characteristic of its usual operations. Additionally, the Company is presenting constant currency information to provide a framework to assess how its business performed excluding the effects of foreign currency exchange rate fluctuations in the current period. Comparisons of financial results on a constant dollar basis are calculated by translating each foreign currency at the same U.S. dollar exchange rate as in effect for the prior-year period for both periods being compared.The Company believes this information is useful to investors to facilitate comparisons of operating results. These non-GAAP financial measures are designed to complement the GAAP financial information presented in this release. The non-GAAP financial measures presented should not be considered in isolation from or as a substitute for the comparable GAAP financial measures, and the methods of their calculation may differ substantially from similarly titled measures used by other companies.

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “expects,” “anticipates,” “believes,” “targets,” “goals,” “projects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “should” and variations of such words and similar expressions. Similarly, statements in this press release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals are also forward-looking statements. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the Company’s actual results, performance or achievements and levels of future dividends to differ materially from those expressed in, or implied by, these statements. These risks and uncertainties may include, but are not limited to, the Company’s ability to implement and maintain effective internal control over financial reporting in the future, plans to remediate the material weakness with respect to the Company’s internal control over financial reporting and disclosure controls and procedures, general economic and business conditions which may impact disposable income of consumers in the United States and the other significant markets (including Europe) where the Company’s products are sold, uncertainty regarding such economic and business conditions, including inflation, elevated interest rates, increased commodity prices and tightness in the labor market, trends in consumer debt levels and bad debt write-offs, general uncertainty related to geopolitical concerns, the impact of international hostilities, including the Russian invasion of Ukraine and war in the Middle East, on global markets, economies and consumer spending, on energy and shipping costs, and on the Company’s supply chain and suppliers, supply disruptions, delivery delays and increased shipping costs, defaults on or downgrades of sovereign debt and the impact of any of those events on consumer spending, evolving stakeholder expectations and emerging complex laws on environmental, social, and governance matters, changes in consumer preferences and popularity of particular designs, new product development and introduction, decrease in mall traffic and increase in e-commerce, the ability of the Company to successfully implement its business strategies, competitive products and pricing, including price increases to offset increased costs, the impact of “smart” watches and other wearable tech products on the traditional watch market, seasonality, availability of alternative sources of supply in the case of the loss of any significant supplier or any supplier’s inability to fulfill the Company’s orders, the loss of or curtailed sales to significant customers, the Company’s dependence on key employees and officers, the ability to successfully integrate the operations of acquired businesses without disruption to other business activities, the possible impairment of acquired intangible assets, risks associated with the Company’s minority investments in early-stage growth companies and venture capital funds that invest in such companies, the continuation of the Company’s major warehouse and distribution centers, the continuation of licensing arrangements with third parties, losses possible from pending or future litigation and administrative proceedings, the ability to secure and protect trademarks, patents and other intellectual property rights, the ability to lease new stores on suitable terms in desired markets and to complete construction on a timely basis, the ability of the Company to successfully manage its expenses on a continuing basis, information systems failure or breaches of network security, complex and quickly-evolving regulations regarding privacy and data protection, the continued availability to the Company of financing and credit on favorable terms, business disruptions, and general risks associated with doing business internationally, including, without limitation, import duties, tariffs (including retaliatory tariffs), quotas, political and economic stability, changes to existing laws or regulations, and impacts of currency exchange rate fluctuations and the success of hedging strategies related thereto, and the other factors discussed in the Company’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Be advised that developments subsequent to this press release are likely to cause these statements to become outdated with the passage of time. The Company assumes no duty to update its forward-looking statements and this release shall not be construed to indicate the assumption by the Company of any duty to update its outlook in the future.

(Tables to follow)

MOVADO GROUP, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
 
 
Three Months Ended Twelve Months Ended
January 31, January 31,
 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

(As Restated) (As Restated)
Net sales

$

181,475

 

$

175,753

 

$

653,378

 

$

664,389

 

 
Cost of sales

 

83,137

 

 

81,659

 

 

300,238

 

 

300,230

 

 
Gross profit

 

98,338

 

 

94,094

 

 

353,140

 

 

364,159

 

 
Total operating expenses

 

89,116

 

 

83,311

 

 

333,125

 

 

315,689

 

 
Operating income

 

9,222

 

 

10,783

 

 

20,015

 

 

48,470

 

 
Non-operating income/(expense):
Other income, net

 

1,554

 

 

1,800

 

 

7,125

 

 

5,994

 

Interest expense

 

(117

)

 

(136

)

 

(489

)

 

(497

)

 
Income before income taxes

 

10,659

 

 

12,447

 

 

26,651

 

 

53,967

 

 
Provision for income taxes

 

2,201

 

 

2,348

 

 

7,442

 

 

11,792

 

 
Net income

 

8,458

 

 

10,099

 

 

19,209

 

 

42,175

 

 
Less: Net income attributable to noncontrolling interests

 

405

 

 

262

 

 

845

 

 

830

 

 
Net income attributable to Movado Group, Inc.

$

8,053

 

$

9,837

 

$

18,364

 

$

41,345

 

 
Diluted Income Per Share Information
Net income per share attributable to Movado Group, Inc.

$

0.36

 

$

0.43

 

$

0.81

 

$

1.83

 

 
Weighted diluted average shares outstanding

 

22,534

 

 

22,708

 

 

22,603

 

 

22,641

 

MOVADO GROUP, INC.
GAAP AND NON-GAAP MEASURES
(In thousands, except for percentage data)
(Unaudited)
 
 
Three Months Ended
January 31,

% Change

 

 

2025

 

2024

 

(As Restated)

 

Total net sales, as reported

$

181,475

$

175,753

3.3%

 

Total net sales, constant dollar basis

$

184,561

$

175,753

5.0%

 

 

 

Twelve Months Ended

 

January 31,

% Change

 

 

2025

 

2024

 

(As Restated)

 

Total net sales, as reported

$

653,378

$

664,389

-1.7%

 

Total net sales, constant dollar basis

$

654,728

$

664,389

-1.5%

MOVADO GROUP, INC.
GAAP AND NON-GAAP MEASURES
(In thousands, except per share data)
(Unaudited)
 
Net Sales Gross Profit Total Operating
Expenses
Operating
Income
Pre-tax Income Provision/(Benefit)
for Income Taxes
Net Income
Attributable to
Movado Group, Inc.
Diluted EPS
Three Months Ended January 31, 2025
As Reported (GAAP)

$

181,475

$

98,338

$

89,116

 

$

9,222

$

10,659

$

2,201

 

$

8,053

$

0.36

Cost-Savings Initiative (1)

 

 

 

(1,817

)

 

1,817

 

1,817

 

277

 

 

1,540

 

0.07

Professional fees (2)

 

 

 

(2,500

)

 

2,500

 

2,500

 

608

 

 

1,892

 

0.08

Adjusted Results (Non-GAAP)

$

181,475

$

98,338

$

84,799

 

$

13,539

$

14,976

$

3,086

 

$

11,485

$

0.51

 
 
Three Months Ended January 31, 2024 (As Restated)
As Reported (GAAP)

$

175,753

$

94,094

$

83,311

 

$

10,783

$

12,447

$

2,348

 

$

9,837

$

0.43

 
 
Net Sales Gross Profit Total Operating
Expenses
Operating
Income
Pre-tax Income Provision/(Benefit)
for Income Taxes
Net Income
Attributable to
Movado Group, Inc.
Diluted EPS
Twelve Months Ended January 31, 2025
As Reported (GAAP)

$

653,378

$

353,140

$

333,125

 

$

20,015

$

26,651

$

7,442

 

$

18,364

$

0.81

Cost-Savings Initiative (1)

 

 

 

(4,552

)

 

4,552

 

4,552

 

838

 

 

3,714

 

0.16

Professional fees

 

 

 

(2,500

)

 

2,500

 

2,500

 

608

 

 

1,892

 

0.08

Repatriation of Foreign Earnings (3)

 

 

 

 

 

 

 

(1,458

)

 

1,458

 

0.07

Adjusted Results (Non-GAAP)

$

653,378

$

353,140

$

326,073

 

$

27,067

$

33,703

$

7,430

 

$

25,428

$

1.12

 
 
Twelve Months Ended January 31, 2024 (As Restated)
As Reported (GAAP)

$

664,389

$

364,159

$

315,689

 

$

48,470

$

53,967

$

11,792

 

$

41,345

$

1.83

(1)

  Related to the establishment of provisions associated with a corporate cost-savings initiative.

(2)

  Professional fees related to the investigation of allegations of misconduct within the Dubai branch of the Company’s Swiss subsidiary that resulted in a restatement of previously issued financial statements.

(3)

  Tax impact of repatriation of foreign earnings, primarily related to foreign currency gains.
MOVADO GROUP, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
 

 

January 31, January 31,

 

2025

2024

 

(As Restated)
ASSETS

 

 

 

Cash and cash equivalents

 

$

208,501

$

262,059

Trade receivables, net

 

 

93,382

 

86,044

Inventories

 

 

156,738

 

153,890

Other current assets

 

 

21,786

 

17,962

Income taxes receivable

 

 

9,534

 

11,339

Total current assets

 

 

489,941

 

531,294

 

Property, plant and equipment, net

 

 

19,920

 

19,436

Operating lease right-of-use assets

 

 

86,009

 

82,661

Deferred and non-current income taxes

 

 

41,330

 

43,016

Other intangibles, net

 

 

5,537

 

7,493

Other non-current assets

 

 

86,494

 

72,598

Total assets

 

$

729,231

$

756,498

 

LIABILITIES AND EQUITY

 

 

 

Accounts payable

 

$

34,312

$

32,775

Accrued liabilities

 

 

42,610

 

38,695

Accrued payroll and benefits

 

 

7,840

 

7,591

Current operating lease liabilities

 

 

19,263

 

15,696

Income taxes payable

 

 

8,935

 

16,642

Total current liabilities

 

 

112,960

 

111,399

 

Deferred and non-current income taxes payable

 

 

1,008

 

8,234

Non-current operating lease liabilities

 

 

75,508

 

76,396

Other non-current liabilities

 

 

56,176

 

52,420

 

Shareholders’ equity

 

 

481,329

 

505,890

 

Noncontrolling interest

 

 

2,250

 

2,159

Total equity

 

 

483,579

 

508,049

 

Total liabilities and equity

 

$

729,231

$

756,498

 
MOVADO GROUP, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
 

Twelve Months Ended

January 31,

 

 

2025

 

 

2024

 

Cash flows from operating activities: (As Restated)
Net income

$

19,209

 

$

42,175

 

Depreciation and amortization

 

9,312

 

 

9,644

 

Other non-cash adjustments

 

9,548

 

 

14,921

 

Changes in working capital

 

(34,884

)

 

8,770

 

Changes in non-current assets and liabilities

 

(4,689

)

 

1,268

 

Net cash (used in)/provided by operating activities

 

(1,504

)

 

76,778

 

 
Cash flows from investing activities:
Capital expenditures

 

(7,966

)

 

(8,223

)

Long-term investments

 

(5,667

)

 

(3,107

)

Trademarks and other intangibles

 

(109

)

 

(144

)

Net cash used in investing activities

 

(13,742

)

 

(11,474

)

 
Cash flows from financing activities:
Dividends paid

 

(31,069

)

 

(53,146

)

Stock repurchases

 

(2,628

)

 

(3,116

)

Distribution of noncontrolling interest earnings

 

(604

)

 

(1,431

)

Stock awards and options exercised and other changes

 

(1,101

)

 

97

 

Net cash used in financing activities

 

(35,402

)

 

(57,596

)

 
Effect of exchange rate changes on cash, cash equivalents, and restricted cash

 

(2,952

)

 

2,927

 

Net change in cash, cash equivalents, and restricted cash

 

(53,600

)

 

10,635

 

Cash, cash equivalents, and restricted cash at beginning of period

 

262,814

 

 

252,179

 

 
Cash, cash equivalents, and restricted cash at end of period

$

209,214

 

$

262,814

 

 
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents

$

208,501

 

$

262,059

 

Restricted cash included in other non-current assets

 

713

 

 

755

 

Cash, cash equivalents, and restricted cash

$

209,214

 

$

262,814

 

 

ICR, Inc.

Allison Malkin

203-682-8225

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Jewelry Fashion Other Retail Luxury Retail

MEDIA: